

1 **Clinical Practice Guideline: Electrodiagnostic Testing**

2
3 **Date of Implementation: June 23, 2010**

4
5 **Product: Specialty**

6
7
8 **GUIDELINES**

9 **Medically Necessary**

10 **Nerve Conduction/Electromyography: Performed Together**

11 Nerve conduction velocity (NCV) testing AND needle electromyography testing
12 (NEMG) are considered medically necessary when they are conducted and interpreted at
13 the same time for ANY of the following indications:

- 14 • Myopathy, including but not limited to ANY of the following:
- 15 ○ Inflammatory myopathy and myositis (i.e, polymyositis, dermatomyositis,
16 inclusion body myositis)
 - 17 ○ Congenital and hereditary dystrophic and nondystrophic myopathies,
18 including myotonic muscular dystrophy
 - 19 ○ Acquired myopathies (drug induced myopathy associated with statins,
20 thyroid related)
 - 21 ○ Metabolic myopathies (such as McArdle disease)
- 22 • Disorder of brachial or lumbosacral plexus (e.g., inflammatory, idiopathic,
23 traumatic, infiltrative plexopathy, thoracic outlet syndrome, Parsonage Turner
24 syndrome)
- 25 • Motor or sensory neuronopathy or ganglionopathy (e.g., Amyotrophic lateral
26 sclerosis, primary lateral sclerosis, progressive muscular atrophy or Kennedy's
27 Disease)
- 28 • Multifocal motor neuropathy
- 29 • Neuromuscular junction disorder (e.g., myasthenia gravis, Lambert-Eaton
30 myasthenic syndrome, botulism)
- 31 • Focal or generalized sensory and motor neuropathies including but not limited to
32 ANY of the following after failure of 4-6 weeks of conservative care (e.g., physical
33 therapy, exercise, bracing):
- 34 ○ carpal tunnel syndrome
 - 35 ○ cubital tunnel syndrome or ulnar neuropathy
 - 36 ○ tarsal tunnel syndrome
 - 37 ○ cervical or lumbar radiculopathy
- 38 • Inflammatory/autoimmune polyneuropathy (e.g., Guillain-Barre syndrome,
39 chronic inflammatory demyelinating polyneuropathy [CIDP], mononeuritis
40 multiplex and neuropathy associated with rheumatologic disorders)
- 41 • Hereditary neuropathies (e.g., Charcot-Marie-Tooth disease, hereditary
42 neuropathy with liability to pressure palsies, Friedreich's Ataxia)

- 1 • Diabetic polyneuropathy and diabetic radiculoplexus neuropathy (diabetic
- 2 amyotrophy)
- 3 • Metabolic and nutritional neuropathy (e.g., vitamin B12 or thiamine deficiency)
- 4 • Toxic neuropathy (associate with drugs vincristine, amiodarone or environmental
- 5 toxins such as organophosphates)
- 6 • Infectious neuropathy (e.g., HIV, Lyme disease, Leprosy, polio)
- 7 • Cranial neuropathy (Bell’s or facial palsy)
- 8 • Idiopathic peripheral neuropathy
- 9 • Symptom-based presentation suggesting nerve root, peripheral nerve, muscle, or
- 10 neuromuscular junction involvement, when pre-test evaluations are inconclusive
- 11 and clinical assessment supports the need for the study, such as for ANY of the
- 12 following:
- 13 ○ Muscle weakness
- 14 ○ Muscle atrophy
- 15 ○ Muscle fasciculation
- 16 ○ Myokymia
- 17 ○ Myotonia
- 18 ○ Loss of dexterity
- 19 ○ Spasticity
- 20 ○ Hyperreflexia
- 21 ○ Sensory deficits
- 22 ○ Diplopia
- 23 ○ Ptosis
- 24 ○ Swallowing dysfunction
- 25 ○ Dysarthria
- 26 ○ Impaired bowel motility

27

28 **Nerve Conduction: Performed Alone**

29 Nerve conduction velocity (NCV) testing performed alone is considered medically
 30 necessary for ANY of the above indications, in ANY of the following clinical
 31 presentations:

- 32 • Current use of an anticoagulant
- 33 • Presence of significant lymphedema
- 34 • For facial nerve monitoring in Bells palsy
- 35 • Suspected peroneal/fibular nerve palsy
- 36 • Thoracic outlet syndrome
- 37 • Suspected tarsal tunnel syndrome
- 38 • Suspected acute nerve injury (within 3 weeks)

- 1 • Carpal tunnel syndrome with BOTH of the following:
- 2 ○ with high pre-test probability (e.g., positive Tinel’s, thenar muscle atrophy
- 3 or paresthesia in the radial three digits)
- 4 ○ after failure of 4-6 weeks of conservative care (e.g., physical therapy,
- 5 exercise, bracing)

6

7 NEMG testing is considered medically necessary when performed for determination of

8 precise muscle location for an injection (i.e., prior to botulism toxin injection for

9 localization; prior to injection of phenol or other substances for nerve blocking or

10 chemodenervation).

11

12 **Neuromuscular Junction Testing**

13 Neuromuscular junction testing is considered medically necessary for ANY of the

14 following indications:

- 15 • Myopathy
- 16 • Motor neuropathy (e.g., ALS)
- 17 • Botulinum toxicity
- 18 • Myasthenia gravis
- 19 • Lambert Eaton myasthenic syndrome
- 20 • The presence of any of the following:
- 21 ○ Diplopia
- 22 ○ Dysphagia and dysarthria
- 23 ○ Fatigue/weakness that progresses with repetitive activity

24

25 Single fiber EMG (SFEMG) is medically necessary for diagnosis of myasthenia gravis

26 if repetitive nerve stimulation is negative or inconclusive.

27

28 **Somatosensory Evoked Potentials (SSEPs)**

29 Somatosensory evoked potentials (SSEPs) are considered medically necessary when

30 prior diagnostic testing has failed to confirm a diagnosis for ANY of the following:

- 31 • Coma following traumatic, hypoxic/ischemic and other diffuse brain injuries
- 32 • Multiple sclerosis and other demyelinating diseases (e.g.,
- 33 adrenoleukodystrophy, adrenomyeloneuropathy, metachromatic
- 34 leukodystrophy, and pelizaeus-merzbacher disease)
- 35 • Spinocerebellar degeneration
- 36 • Spinal cord lesions secondary to trauma when the need for surgical intervention is
- 37 uncertain
- 38 • Acute (within 72 hours) anoxic encephalopathy
- 39 • To localize the cause of a central nervous system deficit seen on exam, but not
- 40 explained by lesions seen on CT or MRI suspected brain death

Not Medically Necessary

Neuromuscular junction testing for ANY other indication is considered not medically necessary.

Nerve conduction velocity testing when performed with NEMG testing for ANY other indication, including the following is considered not medically necessary:

- Screening of the general population, in the absence of related symptoms
- Screening, monitoring of disease intensity or monitoring of treatment efficacy for polyneuropathy of diabetes
- Screening, monitoring of disease intensity or monitoring of treatment efficacy for end stage renal disease

Unproven

The following electrodiagnostic tests are each considered unproven:

- Nerve conduction velocity (NCV) testing performed without needle electromyography, other than when performed for follow-up testing, with current use of anticoagulants, the presence of lymphedema, or for carpal tunnel syndrome
- Nerve conduction testing where the interpretation is delayed and not completed at the time of testing
- Nerve conduction velocity testing performed without the direct supervision of a trained electrodiagnostic physician
- Automated noninvasive nerve conduction testing (e.g., NC-stat System, Brevio[®] nerve conduction monitoring system)
- Macro electromyography (EMG)
- Surface electromyography (e.g., surface EMG [SEMG], surface scanning EMG, high-density SEMG, HD-SEMG) and macro EMGs
- Paraspinal SEMG
- Needle electromyography study performed without a nerve conduction velocity study and/or late response study for any indication, other than injection localization or intraoperative monitoring
- Exclusive testing of intrinsic foot muscles in the diagnosis of proximal lesions
- Definitive diagnostic conclusions based on paraspinal EMG in regions bearing scar of past surgeries (e.g., previous laminectomies)
- Pattern-setting limited limb muscle examinations, without paraspinal muscle testing for a diagnosis of radiculopathy
- EMG testing shortly after trauma, before EMG abnormalities would have reasonably had time to develop
- Multiple uses of EMG in the same patient at the same location of the same limb for the purpose of optimizing botulinum toxin injections

1 SSEPs are considered unproven for ANY indication other than those listed above;
2 including the evaluation of disorders of the lumbosacral roots, such as radiculopathies,
3 thoracic root disorders, or cervical root disorders.

4

5 Current Perception Threshold/Sensory Nerve Conduction Threshold TEST (sNCT) – is
6 not covered by Medicare. This procedure is different and distinct from assessment of
7 nerve conduction velocity, amplitude and latency. It is also different from short-latency
8 somatosensory evoked potentials.

1 **Related CPT® Codes and Descriptions**

| CPT® Codes | CPT® Code Description |
|-------------------|--|
| 95885 | Needle electromyography, each extremity, with related paraspinal areas, when performed, done with nerve conduction, amplitude and latency/velocity study; limited (List separately in addition to code for primary procedure) |
| 95886 | Needle electromyography, each extremity, with related paraspinal areas, when performed, done with nerve conduction, amplitude and latency/velocity study; complete, five or more muscles studied, innervated by three or more nerves or four or more spinal levels (List separately in addition to code for primary procedure) |
| 95887 | Needle electromyography, non-extremity (cranial nerve supplied or axial) muscle(s) done with nerve conduction, amplitude and latency/velocity study (List separately in addition to code for primary procedure) |
| 95905 | Motor and/or sensory nerve conduction, using preconfigured electrode array(s), amplitude and latency/velocity study, each limb, includes F-wave study when performed, with interpretation and report |
| 95907 | Nerve conduction studies; 1-2 studies |
| 95908 | Nerve conduction studies; 3-4 studies |
| 95909 | Nerve conduction studies; 5-6 studies |
| 95910 | Nerve conduction studies; 7-8 studies |
| 95911 | Nerve conduction studies; 9-10 studies |
| 95912 | Nerve conduction studies; 11-12 studies |
| 95913 | Nerve conduction studies; 13 or more studies |
| 95925 | Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in upper limbs |
| 95926 | Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in lower limbs |
| 95927 | Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in the trunk or head |
| 95937 | Neuromuscular junction testing (repetitive stimulation, paired stimuli), each nerve, any 1 method |
| 95938 | Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in upper and lower limbs |
| S3900 | Surface electromyography (EMG) |

1 DESCRIPTION

2 This guideline addresses electrodiagnostic testing, including nerve conduction (NCV)
3 studies, neuromuscular junction testing, electromyography (EMG) studies (including
4 surface EMG). This guideline adopts many of the recommendations for the clinical
5 necessity, contraindications, and proper performance of nerve conduction studies, needle
6 electromyography, and somatosensory evoked potentials (SEPs) from the American
7 Association of Neuromuscular & Electrodiagnostic Medicine (AANEM).

9 GENERAL BACKGROUND

10 Electrodiagnostic studies are frequently used to evaluate a subset of patients with suspected
11 neuromuscular disorders and include needle electromyography and other nerve stimulation
12 tests such as nerve conduction studies. Electrodiagnostic testing may provide an important
13 means of diagnosing conditions attributable to nerve, muscle or neuromuscular junction
14 weakness such as myopathies (muscle weakness), radiculopathies (nerve root disease),
15 plexopathies (peripheral neuropathy), neuropathies (nerve disease), neuromuscular junction
16 disorders, and nerve compression syndromes. In addition, electrodiagnostic testing may be
17 indicated for symptom-based presentations, (e.g., pain in limb, muscle weakness) when
18 appropriate pre-test evaluations are inconclusive and the clinical assessment unequivocally
19 supports the need for the study (American Association of Neuromuscular and
20 Electrodiagnostic Medicine [AANEM], 2010).

22 Electrodiagnostic Testing Nerve Conduction/Needle Electromyography

23 Nerve conduction studies (NCS), also referred to as nerve conduction velocity studies, are
24 performed to diagnose disorders of the peripheral nervous system. Nerve conduction
25 studies are used to measure action potentials resulting from peripheral nerve stimulation
26 which are recordable over the nerve or from an innervated muscle. With this technique,
27 responses are measured between two sites of stimulation, or between a stimulus and a
28 recording site. Recording of the electrical response to stimulation of the nerve between
29 these points along its route is conducted and compared to normal responses. The study
30 measures speed (conduction velocity and/or latency), amplitude (size) and the shape of
31 neurologic response for detecting demyelination and axon loss.

33 Nerve conduction studies are of two general types: sensory and motor. Either surface or
34 needle electrodes can be used to stimulate the nerve or record the response. Axonal damage
35 or dysfunction generally results in loss of nerve or muscle potential response amplitude;
36 whereas demyelination leads to prolongation of conduction time and slowing of conduction
37 velocity.

39 Obtaining and interpreting NCS results requires extensive interaction between the
40 performing qualified health care professional and patient, and is most effective when both

1 obtaining raw data and interpretation are performed concurrently on a real-time basis.
 2 Results of the NCS reflect on the integrity and function of:

- 3 • The myelin sheath (Schwann cell derived insulation covering an axon)
- 4 • The axon (an extension of neuronal cell body) of a nerve

5
 6 Interruption of axon and dysfunction of myelin will both affect NCS results. It is often also
 7 valuable to test conduction status in proximal segments of peripheral nerves. The
 8 stimulation of nerves is similar across all NCSs; the characteristics of motor, sensory, and
 9 mixed NCSs are different and are discussed separately below. In each case, an appropriate
 10 nerve is stimulated, and recording is made either from the appropriate nerves or from
 11 muscle supplied by the motor nerve.

12
 13 Motor NCSs are performed by applying electrical stimulation at various points along the
 14 course of a motor nerve while recording the electrical response from an appropriate muscle.
 15 Response parameters include amplitude, latency, configuration, and motor conduction
 16 velocity.

17
 18 Sensory NCSs are performed by applying electrical stimulation near a nerve and recording
 19 the response from a distant site along the nerve. Response parameters include amplitude,
 20 latency, and configuration.

21
 22 Mixed NCSs are performed by applying electrical stimulation near a nerve containing both
 23 motor and sensory fibers (a mixed nerve) and recording from a different location along that
 24 nerve that also contains both motor and sensory nerve fibers. Response parameters include
 25 amplitude, latency, configuration, and motor conduction velocity."

26
 27 Electromyography (EMG) is the study and recording of intrinsic electrical properties of
 28 skeletal muscles. This is carried out with a needle electrode. Generally, the needles are of
 29 two types: monopolar or concentric. EMG is undertaken together with NCS. Unlike NCS,
 30 however, EMG testing relies on both auditory and visual feedback to the
 31 electromyographer. This testing is also invasive in that it requires needle electrode insertion
 32 and adjustment at multiple sites, and at times anatomically critical sites. As in NCS during
 33 EMG studies the electromyographer depends on ongoing real-time interpretation-based
 34 knowledge of clinical diagnosis being evaluated to decide whether to continue, modify, or
 35 conclude a test. This process requires knowledge of anatomy, physiology, and
 36 neuromuscular diseases.

37
 38 EMG results reflect not only on the integrity of the functioning connection between a nerve
 39 and its innervated muscle but also on the integrity of a muscle itself. The axon innervating
 40 a muscle is primarily responsible for the muscle's volitional contraction, survival, and
 41 trophic functions. Thus, interruption of the axon will alter the EMG. A few prime examples
 42 of conditions in which EMG is potentially helpful are disc disease producing spinal nerve

1 dysfunction, advanced nerve compression in peripheral lesions, Amyotrophic Lateral
2 Sclerosis (ALS), polyneuropathy, etc. After an acute neurogenic lesion, EMG changes may
3 not appear for several days to weeks in the innervated muscles. Primary muscle disease
4 such as polymyositis will also alter a normal EMG pattern. Myotonic disorders may show
5 a pattern of spontaneous repetitive discharges on needle exploration.

6
7 NCS are generally performed with needle electromyogram (NEMG), enabling the presence
8 and extent of peripheral nerve pathology to be determined (Katirji, 2002; North American
9 Spine Society [NASS], 2003; Aminoff, 2003; Asbury, 2004; AANEM 2016). EMG studies
10 measure the electrical activity of muscles. When performed together, they can be extremely
11 helpful in detecting whether the pathology originates in the proximal or distal root ganglia
12 and whether the neuromuscular dysfunction relates to peripheral nerve disease.

13
14 Both EMGs and NCSs are required for a clinical diagnosis of peripheral nervous system
15 disorders. EMG results reflect on the integrity of the functioning connection between a
16 nerve and its innervated muscle and also on the integrity of a muscle itself. Performance of
17 one does not eliminate the need for the other. Without awareness of the patterns of
18 abnormality expected in different diseases and knowledge that the results of nerve
19 conduction studies and electromyography may be similar in different diseases, diagnosis
20 solely by EMG-NCS findings may be both inadequate and ultimately be detrimental to the
21 patient. For example, EMG-NCS findings may overlap in the following pairs of disorders:
22 inflammatory myopathies and ALS, ALS and multi-level radiculopathies, myotonia of
23 channelopathies (periodic paralyses) and myotonic dystrophies, focal neuropathies as
24 Carpal Tunnel Syndrome and proximal plexopathies. Other instances where knowledge of
25 disease behavior is crucial are Chronic Inflammatory Demyelinating Neuropathy (CIDP)
26 and Multifocal Motor Neuropathy. These entities display electrodiagnostic features that
27 resemble generalized polyneuropathies. Neuromuscular transmission disorders require
28 separation based on clinical presentation and electrical features.

29
30 Without awareness of the disease spectrum, diagnosis solely by EMG-NCS findings may
31 be either wrong or detrimental to the patient. Nerve conduction studies performed
32 independent of needle electromyography (EMG) may only provide a portion of the
33 information needed to diagnose muscle, nerve root, and most nerve disorders. When the
34 nerve conduction study (NCS) is used on its own without integrating needle EMG findings
35 or when an individual relies solely on a review of NCS data, the results can be misleading,
36 and important diagnoses may be missed. For example, radiculopathies cannot be
37 definitively diagnosed by NCS alone; EMG is performed to confirm the radiculopathy.
38 According to the American Academy of Neurology (AAN), needle EMG (NEMG), in
39 combination with nerve conduction studies, is the gold standard methodology for assessing
40 the neurophysiologic characteristics of neuromuscular diseases (Pullman et al., 2000). In
41 summary, axonal and muscle involvement are most sensitively detected by EMGs, and
42 myelin and axonal involvement are best detected by NCSs.

1 EMG should always be performed by a physician or health care provider who is specially
2 trained in electrodiagnostic medicine (neurologist, physiatrist, clinical neurophysiologist,
3 board-certified physical therapist) with real-time interpretation (performed only by a
4 physician) and is part of the complete electrodiagnostic examination (AANEM, 2022).
5 EMG reports should include documentation of the muscle tested, the presence and type of
6 spontaneous activity and the characteristics of the voluntary unit potentials.

7
8 NCS may be performed by a trained technologist under the direct supervision of a
9 physician. Direct supervision implies that a physician is in close proximity to the patient
10 undergoing testing, is immediately available to provide the trained technician with
11 assistance and direction if necessary and is responsible for determining the nerve
12 conduction studies that are appropriate. In general, a physician assesses the results of the
13 degree of myelination or axonal loss.

14 15 **H-reflex/F-wave Testing**

16 Late response (H-reflex and F-wave testing) testing is a type of NCS usually performed on
17 nerves more proximal to the spine. The H-reflex involves conduction from the periphery
18 to and from the spinal cord. The H-reflex study involves the assessment of the
19 gastrocnemius/soleus muscle complex in the calf and is usually performed bilaterally due
20 to the need to assess symmetrical results in determining abnormalities. The F-wave study
21 is a late response similar to the H-reflex. F-wave studies are used to assess the proximal
22 segments of the motor nerve function, and are performed in combination with the
23 examination of motor nerves. Both studies are helpful in diagnosing conditions of
24 radiculopathies, plexopathies, polyneuropathies, and proximal mononeuropathies
25 (AANEM, 2022). Late response studies are additional studies complementary to NCV and
26 are performed during the same patient evaluation.

27
28 Single Fiber EMG: Single fiber EMG uses a very highly selective electrode that can focus
29 on a restricted number of muscle fibers. It is utilized to study neuromuscular jitter and
30 muscle fiber density. Fiber density may be increased in neuromuscular disorders such as
31 myasthenia gravis. Jitter is a measure of variation in neuromuscular transmission times and
32 may be increased in some neuromuscular disorders (Sanders, Howard, 2008; Barboi and
33 Barkhaus, 2004; Sanders, 2004). Single fiber EMG has many uses; however, it is most
34 useful to confirm diagnosis for disorders of the neuromuscular junction in suspected
35 myasthenia gravis when other tests are inconclusive or negative (Sanders, Howard, 2008;
36 Gooch and Pullman, 2004).

37 38 **Macro EMG**

39 Macro EMG is less selective when compared to standard NEMG or single-fiber EMG and
40 is primarily used in investigational settings. It is a method of analyzing the motor unit
41 quantitatively. A surface electrode is used for reference, and motor unit action potentials
42 (MUAP) are measured from a macro needle. Authors suggest that macro EMG evaluates a

1 large recording area compared to other needle electrodes and is considered representative
2 of the entire MUAP area (Barboi and Barkhous, 2004).

4 **Surface EMG (SEMG)**

5 In contrast to NEMG, SEMG, also referred to as surface scanning EMG, is a noninvasive,
6 computer-based technique that records the electrical impulses using electrodes placed on
7 the surface of the skin overlying the nerve at rest (i.e., static) and during activity (i.e.,
8 dynamic). The procedure studies the topography of the motor unit action potential
9 (MUAP) and is assessed by computer analysis of the frequency spectrum, amplitude or
10 root mean square of the electrical action potential. The SEMG differs from the NEMG
11 with respect to technical requirements and electrical properties. SEMG electrodes
12 measure from a wide area of muscle, have a relatively narrow frequency band (range 20
13 to 500 Hz), have low-signal resolution, and are highly susceptible to movement artifact
14 (Pullman, 2000). The proposed use for this type of EMG is to aid in the diagnosis of
15 neuromuscular disorders and low back pain, and to aid in assessing the prognosis of
16 disorders involving muscle lesions. The technology has also been used to monitor
17 bruxism (i.e., grinding and clenching of teeth). The electrical activity of muscle may be
18 recorded with surface EMG, although spontaneous electrical activity and voluntary motor
19 units cannot be (Lange and Trojaborg, 2000). Although not widely used as a diagnostic
20 tool, high-density SEMG (HD-sEMG) is a multichannel SEMG that records the input of
21 multiple electrodes placed on one muscle and is being studied as a possible method of
22 detecting single MU characteristics (Drost et al., 2006). Nonetheless, the clinical utility
23 of surface EMG testing outside of the investigative setting has not been proven in the
24 peer-reviewed scientific literature.

26 **Paraspinal EMG**

27 Paraspinal EMG scanning, a type of SEMG, also referred to as paraspinal SEMG, has been
28 investigated as a method of assessing the paraspinal muscles of patients which provide
29 support to the spinal column. Impairment of the paraspinal muscles may lead to abnormal
30 motion and pain. The paraspinal SEMG is performed using a single electrode or an array
31 of electrodes placed on the skin surface with recordings that are typically made at rest, in
32 various positions, or after physical activity. The diagnostic utility of paraspinal EMG is not
33 known, and its role in patient management has not been established.

35 **Somatosensory Evoked Potentials (SEPs)**

36 SEPs are an extension of the electrodiagnostic evaluation and can be used to test
37 conduction in various sensory fibers of the peripheral and central nervous systems. SEPs
38 may be used to assess the functional integrity of the central and peripheral sensory
39 pathways. SEPs are noninvasive studies performed by repetitive submaximal stimulation
40 of a sensory or mixed sensorimotor peripheral nerve and recording the averaged responses
41 from electrodes placed over proximal portions of the nerve stimulated, plexus, spine, and
42 scalp (AANEM, 2015). SSEPs are an extension of the electrodiagnostic evaluation and are

1 used to evaluate nerves that cannot be studied by conventional nerve conduction studies,
2 including electromyography. SEPs are typically elicited by stimulating mixed nerves
3 (median, ulnar, tibial, and peroneal) to assess sensory pathways. Therefore, the application
4 of standard SEPs to study radicular disease is necessarily limited to investigating the
5 lumbar and cervical regions because of the limited number of sites to stimulate (AAN,
6 1997).

7
8 The evoked potential response depends on the functional integrity of the nerve that is
9 stimulated. An abnormal SSEP points to a problem in the nerve conduction mechanism
10 that carries the impulse to the brain, however, the SSEP abnormality is not disease
11 specific—an abnormal SSEP indicates impairments associated with certain disorders. An
12 abnormal SSEP signifies an impaired pathway, helps to localize it, and provides a
13 prognostic guide. The SSEP does not provide any indication about the nature of the
14 underlying pathological processes. Although evoked potentials offer additional
15 information regarding function that can be clinically useful, magnetic resonance imaging
16 (MRI) is often the preferred test to determine structural abnormalities and provides more
17 specific information regarding neurologic structures.

18
19 SSEPs are altered by impairment of the somatosensory pathway which may occur as a
20 result of both diffuse (e.g., diseases of myelin, hereditary system degenerations, coma) or
21 local disorders (e.g., tumors, vascular lesions). SSEP abnormalities can be detected in a
22 variety of different settings; therefore, the electrophysiologic findings should be interpreted
23 in the clinical context in which they are obtained (e.g., assessing functional integrity,
24 diagnostic purposes, determining the course of neurological disorders, determining
25 pathological involvement). SSEPS are helpful in evaluating ill-defined complaints. A
26 physician assesses the patient and determines a preliminary differential diagnosis; SSEP
27 testing may then be performed by a trained technologist under the direct supervision of a
28 trained electrodiagnostic physician. Direct supervision implies that a physician is in close
29 proximity to the patient undergoing testing, is immediately available to provide the trained
30 technician with assistance and direction if necessary and is responsible for determining the
31 SSEP studies that are appropriate.

32
33 Evoked potentials are used to assist in diagnosing ill-defined neurological conditions and
34 to categorize afferent pathways that may be responsible for the resulting symptoms
35 experienced by the patient. Conditions for which SSEPS may offer clinical utility include
36 (American Association of Neuromuscular and Electrodiagnostic Medicine [AANEM],
37 2015):

- 38 • Spinal cord trauma
- 39 • Subacute combined degeneration
- 40 • Non-traumatic spinal cord lesions (e.g., cervical spondylosis)
- 41 • Multiple sclerosis
- 42 • Spinocerebellar degeneration

- 1 • Myoclonus
- 2 • Coma

3
4 SSEPs have been utilized to evaluate other peripheral nerve disorders such as acute
5 inflammatory demyelinating polyradiculoneuropathy and focal neuropathies (e.g.,
6 entrapment neuropathies, carpal tunnel syndrome, lateral femoral cutaneous neuropathy,
7 medial and lateral plantar neuropathy, saphenous neuropathy, intercostals neuropathy,
8 trigeminal neuropathy, plexopathy) in addition to nerve root dysfunction (i.e., lumbosacral
9 root [acute radiculopathies], thoracic root, cervical root). However, the diagnostic utility
10 of SSEPs for these conditions remains controversial (AANEM, 2015). The AANEM
11 reported that the available evidence is not convincing that SSEPs for these indications
12 provide information that cannot be obtained with conventional nerve conduction studies or
13 needle electromyography. SSEPs are rarely used to assess peripheral neuropathy as
14 standard nerve conduction velocity studies are the preferred test. There are no data to
15 suggest a role for SSEPs in the evaluation of behavioral health disorders. The usefulness
16 of evoked potential testing in psychiatry, including SSEPs, is still under investigation
17 (Guse and Love, 2005). Recordings of SSEP can be normal even in patients with extreme
18 sensory deficits due to the presence of multiple parallel, afferent somatosensory pathways.
19 This procedure is often performed to investigate patients with multiple sclerosis (MS);
20 various coma states, such as those from post-traumatic injury or post-anoxia; suspected
21 brain death; and to indicate the extensiveness of lesion damage in spinal cord injuries. The
22 return or presence of a cortically-generated response to stimulation of a nerve below the
23 injured portion of the cord indicates an incomplete lesion and therefore may offer a better
24 prognosis. SSEP testing is typically performed bilaterally. Depending on the clinical
25 situation being investigated, several nerves in one extremity may have to be tested and
26 compared with the opposite limb. The physician's SSEP report should indicate which
27 nerves were tested, latencies at various testing points and an evaluation of whether the
28 results were normal or abnormal.

29 30 **Neuromuscular Junction Testing**

31 The neuromuscular unit is made up of four components: the anterior horn cells of the spinal
32 cord, the peripheral nerve, the neuromuscular junction, and the muscle being innervated.
33 The level of disease determines the signs and symptoms an individual develops.
34 Neuromuscular junction testing involves the stimulation of an individual motor nerve by
35 means of repetitive electrical impulses with measurement of the resulting electrical activity
36 of a muscle supplied by that nerve. Supramaximal electrical stimuli are delivered to the
37 nerve. A surface electrode over, or percutaneous electrode placed in, a corresponding
38 muscle records the evoked muscle action potentials using standard nerve conduction study
39 techniques. The nerve is then stimulated electrically in a repetitive train at 2-3 Hz, or in
40 special circumstances at higher rates up to 50 Hz. Testing may be performed in addition to
41 NCS of the same nerves and/or EMG. In diseases of the neuromuscular junction,
42 characteristic changes of a progressive decrease (decrement) in the compound action

1 potential amplitude may be seen during the repetitive stimulation. Testing is indicated for
2 suspected diseases of the neuromuscular junction (generally associated with progressive
3 motor fatigability) which include myopathy, focal neuropathy, myasthenia gravis and
4 Lambert Eaton myasthenic syndrome. Another condition that testing may be indicated for,
5 botulism, is associated with a decrease in the amount of acetylcholine released, and results
6 in weakness (Juel, 2012; Shearer, Jagoda, 2009).

7 8 **Automated Nerve Conduction Testing**

9 Proponents of automated nerve conduction tests suggest that they can be used in a variety
10 of clinical settings, including a physician’s office, without the need for specialized training
11 or equipment, theoretically obtaining results within minutes. Portable, automated devices
12 have been developed to provide nerve conduction studies at the point of care (e.g., primary
13 care setting), particularly for carpal tunnel evaluation and evaluation of diabetic peripheral
14 neuropathy, as an alternative to or as an adjunct to other conventional testing methods.
15 Manufacturers state these devices have computational algorithms, provide delivery of
16 stimulus, measure and analyze the patient’s response, and provide a detailed report of study
17 results.

18
19 The NC-stat System and ADVANCE™ NCS system (NEUROMetrix® Inc., Waltham,
20 MA) are hand-held, noninvasive, automated nerve conduction testing systems that have
21 been proposed as an alternative to conventional nerve conduction testing. The devices have
22 been marketed for use in an office or clinic setting, to assess nerves of the upper and lower
23 extremities assisting in the diagnosis of peripheral nerve disorders such as carpal tunnel
24 syndrome, diabetic peripheral neuropathy, and sciatica. The manufacturer suggests that
25 data can be analyzed and readily available within minutes and then transmitted to the
26 physician via email, internet or as a faxed document. A computerized system interprets the
27 data. The proposed benefits of these devices are ease of use and rapid results.

28
29 Another device proposed for automated testing of peripheral nerves is the Brevio nerve
30 conduction monitoring system (Neurotron Medical, Inc., West Trenton, NJ). According to
31 the manufacturer, the device calculates latency and amplitude for sensory, motor, and f-
32 wave responses using a single noninvasive neuro-sensor for testing performed on the
33 patient. Similar to the NC-stat device, when testing is performed, the results can be
34 immediately sent to a printer in the office or through a Web service for an electronic report.

35 36 **Electrodiagnostic Testing General Principles**

37 Electrodiagnostic testing of nerve function is established as having diagnostic utility and
38 is professionally recognized when such tests are ordered to clarify or confirm findings from
39 history and physical examination including a neurological examination as described within
40 this guideline. Current guidelines do not support the use of these tests for initial or routine
41 screening of patients in the absence of findings from physical examination or when the
42 results of such tests are unlikely to influence treatment planning or patient management.

1 In order to establish the necessity for special diagnostic testing, one needs to consider at
2 least the following:

- 3 • Is there historical or chief complaint information that suggests a condition or lesion
4 that can only be appropriately evaluated using special tests or was an appropriate
5 physical examination performed that brought forth findings suggestive of a
6 condition or lesion that can only be appropriately evaluated using special tests?
- 7 • For nerve function tests specifically, was a neurological examination of reflexes,
8 sensory integrity, and motor function performed as part of the physical examination
9 and were findings indicative of nerve insult (diminished reflexes, dermatome-
10 specific sensory deficits, or nerve-root-specific muscle weakness)?
- 11 • Would the anticipated information or clarification from the results of the special
12 tests influence treatment planning?
- 13 • If there is a strong indication for special testing because of suspicious findings on
14 history or physical examination, would positive findings on special tests necessitate
15 referral to a specialist where such testing might be repeated or duplicated;
16 specifically, is the test most appropriately performed or ordered by the clinician
17 evaluating the patient or by a specialist to whom the patient should be referred?

18
19 When patients present with neck or low back pain with associated extremity complaints of
20 pain, numbness, or tingling it is hoped that a pattern match can be made between these
21 complaints and objective physical examination demonstration of sensory loss, motor loss,
22 or an associated deep tendon reflex decrease. Use of provocative maneuvers such as
23 compression, distraction, or percussive maneuvers (e.g., Cervical Compression Test,
24 Straight Leg Raise, Tinel’s sign) may further clarify the diagnosis. Other sources of the
25 complaint should also be evaluated including referral from trigger points or facet irritation.
26 Management should be based on the suspected cause. Consideration of electrodiagnostic
27 testing may be warranted when:

- 28 • The diagnosis and treatment plan are not confirmed by the history and physical
29 examination;
- 30 • A preliminary diagnosis and trial of treatment are not resulting in improvement;
- 31 • The patient’s condition does not respond to treatment or worsens; or
- 32 • In order to make a proper diagnosis and treatment plan.

33
34 However, in most cases (i.e., for the conditions referenced above), it would be appropriate
35 to initiate conservative care (e.g., 4-6 weeks), being sure to monitor for worsening or non-
36 response to care, prior to utilizing invasive electrodiagnostic procedures (Souza, 2009).
37 The electrodiagnostic evaluation is an extension of the neurologic portion of the physical
38 examination. Both require a detailed knowledge of a patient and his/her disease. The
39 electrodiagnostic consultation provides useful information in the evaluation of motor,
40 sensory and autonomic neurons, nerve roots, brachial and lumbar plexi, peripheral nerves,
41 neuromuscular junction, and muscles. Electrodiagnostic studies should enhance, but not
42 replace, a careful history and physical examination. Training in the performance of

1 electrodiagnostic procedures in isolation of knowledge about clinical diagnostic and
2 management aspects of neuromuscular diseases, may not be adequate for proper
3 performance of an electrodiagnostic evaluation and correct interpretation of
4 electrodiagnostic test results.

5
6 The broad diagnostic scope of NCS is recognizable by the foregoing description. There
7 may be instances where questions about an indication, or need for a study, will arise. The
8 clinical history and examination, carried out before the study, must always describe and
9 document clearly and comprehensibly the need for the planned test. A "rule-out" diagnosis
10 is typically not acceptable. Often, pain, paresthesia, or weakness in an extremity is the
11 reason for an NCS or EMG. These common symptoms result not only from axonal and
12 myelin dysfunction but also from systemic, non-neurological illnesses. EMG and NCV
13 may help in making this distinction. Therefore, symptom-based diagnoses such as "pain in
14 limb" weakness, disturbance in skin sensation or "paresthesia" are acceptable provided the
15 clinical assessment unequivocally supports the need for a study. To cite but one example
16 of many, an EMG or NCS is irrelevant as a first order diagnostic test for limb pain resulting
17 from immediate antecedent trauma or acute bone injury.

18
19 The intensity and extent of testing with EMG and NCS are matters of clinical judgment
20 developed after the initial pre-test evaluation, and later modified during the testing
21 procedure. Decisions to continue, modify or conclude a test also rely on a knowledge base
22 of anatomy, physiology and neuromuscular diseases. There is a requirement for ongoing
23 real-time clinical diagnostic evaluation, especially during EMG examination. Also, EMG
24 examination is invasive. Needle placement in the exact muscle of interest is essential. It
25 requires needle exploration near vital structures as the pleura, femoral neurovascular
26 bundle, peritoneum, intraspinal spaces, carotid artery, orbit and brachial plexus. Risk of
27 infection from AIDS, Hepatitis B-E, Creutzfeldt-Jakob encephalopathy, and hemorrhage
28 from anticoagulation can be managed by proper techniques. Needle EMG is relatively
29 contraindicated in persons on anti-coagulant therapy with coumadin (Warfarin) or heparins
30 that cannot be interrupted. Oh (2003) observed that patients with a variety of bleeding
31 disorders may be referred for needle EMG. Oh (2003) recommended that the referring
32 physician and the electromyographer examine each case individually, carefully weighing
33 the potential risks and benefits. Cardiac pacemakers and implanted cardiac defibrillators
34 (ICDs) are increasingly used in clinical practice, and no evidence exists indicating that
35 performing routine electrodiagnostic studies on patients with these devices poses a safety
36 hazard. However, there are theoretical concerns that electrical impulses of nerve
37 conduction studies (NCSs) could be erroneously sensed by devices and result in unintended
38 inhibition or triggering of output or reprogramming of the device (Schoeck, 2007). In
39 general, the closer the stimulation site is to the pacemaker and pacing leads, the greater the
40 chance for inducing a voltage of sufficient amplitude to inhibit the pacemaker. Despite
41 such concerns, no immediate or delayed adverse effects have been reported with routine
42 NCS (AANEM, 2014).

1 In patients with external cardiac pacemakers, the conductive lead, inserted into the heart
2 (usually transvenously) and connected to the external cardiac pacemaker, presents a serious
3 potential hazard of electric injury to the heart (Al-Shekhlee et al., 2003). NCSs are not
4 recommended in any patient with an external conductive lead terminating in or near the
5 heart.

6
7 The nature of recurrent and frequent electrical impulses that may occur with repetitive
8 stimulation or eliciting somatosensory evoked potentials (SEP) pose a special
9 circumstance. Nerve stimulation in the lower extremities or in distal upper extremities
10 would be unlikely to have untoward effects upon pacemakers or ICDs. Repetitive
11 stimulation for assessing integrity of the neuromuscular junction typically necessitates
12 study of proximal and/or cranial nerve-innervated muscles, which may place the
13 stimulating electrode closer to the cardiac device. Nonetheless, as there are no data to
14 determine the safety of performing these procedures in patients with pacemakers or ICDs,
15 proximal upper extremity and cranial nerve stimulation sites should be avoided for
16 repetitive and SEP stimulation (AANEM, 2014).

17
18 Needle EMG recording does not introduce electrical current into the body and, therefore,
19 poses no risk of interference with implanted cardiac devices.

20
21 No known contraindications exist from performing needle EMG and NCSs on pregnant
22 patients. In addition, no complications from these procedures have been reported in the
23 literature. Evoked response testing, likewise, has not been reported to cause any problems
24 when performed during pregnancy (AANEM, 2014).

25
26 The minimum standards recommended by the AANEM for electrodiagnostic testing
27 (EDX) include the following:

- 28 1. EDX testing should be medically indicated.
- 29 2. Testing should be performed using EDX equipment that provides assessment of all
30 parameters of the recorded signals. Studies performed with devices designed only
31 for “screening purposes” rather than diagnosis are not acceptable.
- 32 3. The number of tests performed should be the minimum needed to establish an
33 accurate diagnosis.
- 34 4. NCSs should be either (a) performed directly by a physician or (b) performed by a
35 trained individual under the direct supervision of a physician. Direct supervision
36 means that the physician is in close physical proximity to the EDX laboratory while
37 testing is underway, is immediately available to provide the trained individual with
38 assistance and direction, and is responsible for selecting the appropriate NCSs to
39 be performed.
- 40 5. The needle EMG examination must be performed by a physician specially trained
41 in EDX medicine, as these tests are simultaneously performed and interpreted. The
42 EDX laboratory must have the ability to perform needle EMG. The needle EMG

- 1 must include evaluation of both resting and voluntary activities. NCSs should not
 2 be performed without needle EMG except in unique circumstances. EMG and
 3 NCSs should be performed together in the same EDX evaluation when possible.
- 4 6. It is appropriate for only 1 attending physician to perform or supervise all of the
 5 components of the EDX testing (e.g., history taking, physical evaluation,
 6 supervision and/or performance of the EDX test, and interpretation) for a given
 7 patient and for all the testing to occur on the same date of service. The reporting of
 8 NCS and needle EMG study results should be integrated into a unifying diagnostic
 9 impression.
- 10 7. In contrast, dissociation of NCS and needle EMG results into separate reports is
 11 inappropriate unless specifically explained by the physician. Performance and/or
 12 interpretation of NCSs separately from that of the needle EMG component of the
 13 test should clearly be the exception (e.g., when testing an acute nerve injury) rather
 14 than an established practice pattern for a given practitioner.

15
 16 In a position statement published by the AANEM regarding the performance and
 17 interpretation of electrodiagnostic studies (AANEM, 2020), the AANEM states, “To reach
 18 a diagnosis based on EDX testing, it is imperative that the physician has obtained a history
 19 and examined the patient and designed the NCSs and EMG testing based on the
 20 information obtained from the patient. Using a predetermined or standardized battery of
 21 NCSs for all patients is inappropriate because it may be possible to obtain the data needed
 22 to reach a diagnosis with fewer studies. Alternatively, a pre-determined battery may not
 23 include the appropriate NCSs and/or EMG tests to determine the diagnosis. If the EDX
 24 studies are not based on the patient’s history and physical examination findings,
 25 substandard care is being provided. If the NCS results a physician is relying on are
 26 interpreted offsite without integrating information from the needle EMG, substandard care
 27 is being provided. It is the opinion of the AANEM that relying on NCSs alone to make
 28 health care decisions is usually inadequate and inappropriate. .”

29
 30 Except in limited clinical situations, performing nerve conduction studies (NCS) together
 31 with needle electromyography (NEMG) is required to diagnose peripheral nervous system
 32 disorders. According to the AANEM circumstances under which NCS and EMG should
 33 not be performed together include, but are not limited to, limited follow-up studies of
 34 neuromuscular structures that have undergone previous electrodiagnostic evaluation, the
 35 current use of anticoagulants, or the presence of lymphedema. In addition, the AANEM
 36 indicates that for suspected carpal tunnel syndrome, the extent of the needle EMG
 37 examination depends on the results of the NCSs and the differential diagnosis considered
 38 for the individual patient (AANEM, 2022). The AANEM (2022) does not support
 39 screening testing, monitoring disease intensity, or monitoring of treatment efficacy for

1 polyneuropathy of diabetes or polyneuropathy of end stage renal disease (ESRD). NEMG
 2 is also not recommended for any of the following:

- 3 • Testing of intrinsic foot muscles in the diagnosis of proximal lesions
- 4 • Definitive diagnostic conclusion from paraspinal emg in regions bearing scars of
 5 previous surgeries, such as previous laminectomy
- 6 • Pattern setting limited limb muscle examinations without paraspinal muscle testing
 7 for diagnosis of radiculopathy
- 8 • Needle EMG testing performed shortly after trauma

9
 10 **Number of Services Recommended:** Table 1 summarizes the recommendations of the
 11 AANEM regarding the reasonable maximum number of studies per diagnostic category
 12 necessary for a physician to arrive at a diagnosis for 90% of patients with that final
 13 diagnosis, within a 12-month timeframe (AANEM, 2022).

14
 15 **Table 1. Number of Services Recommended:**

| | Limbs Studied by Needle Electromyography (95860-95864, 95867-95870, 95885-95887) | Nerve Conduction Studies (Total nerve studied, 95907-95913) | Neuromuscular Junction Testing (Repetitive Stimulation) |
|--|---|--|--|
| Indication | Number of Services (Tests) | Number of Services (Tests) | Number of Services (Tests) |
| Carpal Tunnel (unilateral) | 1 | 7 | -- |
| Carpal Tunnel (bilateral) | 2 | 10 | -- |
| Radiculopathy | 2 | 7 | -- |
| Mononeuropathy | 1 | 8 | -- |
| Polyneuropathy/ Mononeuropathy Multiplex | 3 | 10 | -- |
| Myopathy | 2 | 4 | 2 |

| | Limbs Studied by Needle Electromyography (95860-95864, 95867-95870, 95885-95887) | Nerve Conduction Studies (Total nerve studied, 95907-95913) | Neuromuscular Junction Testing (Repetitive Stimulation) |
|---|---|--|--|
| Indication | Number of Services (Tests) | Number of Services (Tests) | Number of Services (Tests) |
| Motor Neuronopathy (e.g., ALS) | 4 | 6 | 2 |
| Plexopathy | 2 | 12 | -- |
| Neuromuscular Junction | 2 | 2 | 3 |
| Tarsal Tunnel Syndrome (unilateral) | 1 | 8 | -- |
| Tarsal Tunnel Syndrome (bilateral) | 2 | 11 | -- |
| Weakness, Fatigue, Cramps, or Twitching (focal) | 2 | 7 | 2 |
| Weakness, Fatigue, Cramps, or Twitching (general) | 4 | 8 | 2 |
| Pain, Numbness, or Tingling (unilateral) | 1 | 9 | -- |

| | Limbs Studied by Needle Electromyography (95860-95864, 95867-95870, 95885-95887) | Nerve Conduction Studies (Total nerve studied, 95907-95913) | Neuromuscular Junction Testing (Repetitive Stimulation) |
|---|---|--|--|
| Indication | Number of Services (Tests) | Number of Services (Tests) | Number of Services (Tests) |
| Pain, Numbness, or Tingling (bilateral) | 2 | 12 | -- |

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Carpal Tunnel Syndrome

For suspected carpal tunnel syndrome (CTS), bilateral median motor and sensory NCSs are often indicated. The studies in the contralateral asymptomatic limb serve as controls in cases where values are borderline and may establish the presence of bilateral CTS. Two to 4 additional sensory or mixed NCSs can be compared to the median sensory NCSs to increase the diagnostic sensitivity of the testing. The additional sensory NCSs and an additional motor NCS (usually ulnar) are indicated to exclude a generalized neuropathy or multiple mononeuropathies. If 2 sensitive sensory NCSs are performed at the beginning start, additional sensory testing on the same limb is rarely needed. For suspected bilateral CTS, bilateral median motor and sensory NCSs are indicated. Up to 2 additional motor and 2 additional sensory NCSs are often indicated. The extent of the needle EMG examination depends on the results of the NCSs and the differential diagnosis considered in the individual patient. Additional testing may be indicated in patients with a differential diagnosis which includes peripheral neuropathy, cervical radiculopathy, brachial plexopathy, or more proximal median neuropathy.

Radiculopathy

A minimal evaluation for radiculopathy includes 1 motor and 1 sensory NCS and a needle EMG examination of the involved limb. However, the EDX testing can include up to 3 motor NCSs (in cases of an abnormal motor NCS, the same nerve in the contralateral limb and another motor nerve in the ipsilateral limb can be studied) and 2 sensory NCSs. Bilateral studies are often necessary to exclude a central disc herniation with bilateral radiculopathies or spinal stenosis or to differentiate between radiculopathy and plexopathy, polyneuropathy, or mononeuropathy. H reflexes and F waves may provide useful complementary information and assist in confirmation of root dysfunction. Radiculopathies cannot be diagnosed by NCS alone; needle EMG must be performed to confirm a radiculopathy. Therefore, these studies should be performed together by 1

CPG 129 Revision 14 – S
Electrodiagnostic Testing
Revised – September 21, 2023
To CQT for review 08/14/2023
CQT reviewed 08/14/2023
To QIC for review and approval 09/12/2023
QIC reviewed and approved 09/12/2023
To QOC for review and approval 09/21/2023
QOC reviewed and approved 09/21/2023

1 physician/qualified health care practitioner supervising and/or performing all aspects of the
2 study.

3 **Polyneuropathy/Mononeuropathy Multiplex**

4 In order to characterize the nature of the polyneuropathy (axonal or demyelinating, diffuse
5 or multifocal) and in order to exclude polyradiculopathy, plexopathy, neuronopathy, or
6 multiple mononeuropathies, it may be necessary to study 4 motor and 4 sensory nerves,
7 consisting of 2 motor and 2 sensory NCSs in 1 leg, 1 motor and 1 sensory NCS in the
8 opposite leg, and 1 motor and 1 sensory NCS in 1 arm. H-reflex studies and F-wave studies
9 from 2 nerves may provide additional diagnostic information. At least 2 limbs should be
10 studied by a needle EMG examination. Studies of related paraspinal muscles are indicated
11 to exclude some conditions such as polyradiculopathy.
12

13 **Myopathy**

14 To diagnose a myopathy, a needle EMG examination of 2 limbs is indicated. To help
15 exclude other disorders such as polyneuropathy or neuronopathy, 2 motor and 2 sensory
16 NCSs are indicated. Two repetitive motor nerve stimulation studies may be performed to
17 exclude a disorder of NM transmission.
18

19 **Motor Neuronopathy**

20 In order to establish the diagnosis of motor neuronopathy (e.g., amyotrophic lateral
21 sclerosis and to exclude other disorders in the differential diagnosis, such as multifocal
22 motor neuropathy or polyneuropathy, up to 4 motor nerves and 2 sensory nerves may be
23 studied. Needle EMG of up to 4 extremities (or 3 limbs and facial or tongue muscles) is
24 often necessary to document widespread denervation and to exclude a myopathy. One
25 repetitive motor nerve stimulation study may be indicated to exclude a disorder affecting
26 NMJ transmission.
27

28 **Plexopathy**

29 To characterize a brachial plexopathy and differentiate it from cervical radiculopathy and
30 mononeuropathies it may be necessary to perform additional sensory studies (e.g., medial
31 and lateral antebrachial cutaneous nerves) for a total of up to 6 sensory studies. It may also
32 be necessary to perform up to 4 motor studies.
33

34 To characterize a lumbosacral plexopathy and differentiate it from lumbosacral
35 radiculopathy, mononeuropathies and polyneuropathy, it may be necessary to perform up
36 to 4 sensory studies, up to 4 motor studies and up to 2 H-reflex studies.
37

38 For both brachial and lumbosacral plexopathies, up to 2 additional studies (sensory and/or
39 motor) may be performed in the contralateral (at times asymptomatic) limb to better
40 definite the diagnosis.
41

1 **Neuromuscular Junction**

2 To demonstrate and characterize abnormal NMJ transmission, repetitive nerve stimulation
 3 studies should be performed in up to 3 nerves and single fiber EMG (SFEMG) in up to 2
 4 muscles. If any of these are abnormal, up to 2 motor and 2 sensory NCSs may be performed
 5 to exclude neuropathies that can be associated with abnormal NM transmission. At least 1
 6 motor and 1 sensory NCS should be performed in a clinically involved limb, preferably in
 7 the distribution of a nerve studied with repetitive stimulation or SFEMG. At least 1 distal
 8 and 1 proximal muscle should be studied by a needle EMG examination to exclude a
 9 neuropathy or myopathy that can be associated with abnormal repetitive stimulation studies
 10 or SFEMG. At least 1 of the muscles should be clinically involved and both muscles should
 11 be in clinically involved limbs.

12
 13 In combination, NCSs and a needle EMG examination may be most helpful when
 14 performed several weeks after the injury has occurred. However, NCSs are often useful
 15 acutely after nerve injury, for example, if there is concern that a nerve has been severed. In
 16 fact, if studies are delayed, the opportunity to precisely identify the region of injury or to
 17 intervene may be lost. In some cases, even needle EMG testing performed immediately
 18 after a nerve injury may demonstrate abnormal motor unit action potential (MUAP)
 19 recruitment and/or provide information that can be helpful to document preexisting
 20 conditions, date the injury, or serve as a baseline for comparison with later studies.

21
 22 Because of the variability of different nerve injuries, a standard rule on the timing of EDX
 23 testing cannot easily be established, and the AANEM does not have specific
 24 recommendations in this regard. In all instances, the AANEM encourages dialogue
 25 between physicians and payers, and encourages the appropriate use of the physician's
 26 clinical judgment in determining when studies are most appropriately performed and what
 27 studies should be conducted.

28 29 **Frequency of Electrodiagnostic Testing in a Given Patient**

30 There are many clinical situations where good medical management requires repeat testing,
 31 such as in the following examples:

- 32 1. Second diagnosis. Where a single diagnosis is made on the first visit but the patient
 33 subsequently develops a new set of symptoms, further evaluation is required for a
 34 second diagnosis before treatment can begin.
- 35 2. Inconclusive diagnosis. When a serious diagnosis (e.g., ALS) is suspected but the
 36 results of the needle EMG/NCS examination are insufficient to be conclusive,
 37 follow-up studies are needed to establish or exclude the diagnosis.
- 38 3. Rapidly evolving disease. Initial EDX testing in some diseases may not show any
 39 abnormality (e.g., Guillain-Barré syndrome) in the first 1 to 2 weeks. An early
 40 diagnosis confirmed by repeat electrodiagnosis must be made quickly so treatment
 41 can begin. Follow-up testing can be extremely useful in establishing prognosis and
 42 monitoring patient status.

- 1 4. Course of the disease. Certain treatable diseases such as polymyositis and
2 myasthenia gravis follow a fluctuating course with variable response to treatment.
3 The physician treating such patients needs to monitor the disease progress and the
4 response to therapeutic interventions. The results of follow-up evaluations may be
5 necessary to guide treatment decisions.
- 6 5. Unexpected disease course. In certain situations, management of a diagnosed
7 condition may not yield expected results or new, questionably related problems
8 may occur (e.g., failure to improve following surgery for radiculopathy). In these
9 instances, reexamination is appropriate.
- 10 6. Recovery from injury. Repeat evaluations may be needed to monitor recovery, to
11 help establish prognosis, and/or to determine the need for and timing of surgical
12 intervention (e.g., traumatic nerve injury), and to assess recovery over time
13 following peripheral nerve surgery.

14 Repeat EDX evaluation is, therefore, sometimes necessary and, when justifiable, should be
15 reimbursed. Reasonable limits can be set concerning the frequency of repeat EDX testing
16 per year in a given patient by a given EDX evaluation for a given diagnosis. The following
17 numbers of tests per 12-month period per diagnosis per physician are acceptable:
18

- 19 1. Two tests for carpal tunnel-unilateral, carpal tunnel-bilateral, radiculopathy,
20 mononeuropathy, polyneuropathy, myopathy, and neuromuscular junction (NMJ)
21 disorders.
- 22 2. Three tests for motor neuronopathy, plexopathy, acute inflammatory demyelinating
23 polyradiculoneuropathy/Guillain Barré Syndrome (AIDP/GBS), and following
24 peripheral nerve surgery.
25

26 These limits should not apply if the patient requires evaluation by more than 1 EDX
27 physician (i.e., a second opinion or an expert opinion at a tertiary care center) in a given
28 year or if the patient requires evaluation for a second diagnosis in a given year. Additional
29 studies then may be required or appropriate above these guidelines. In such situations, the
30 reason for the repeat study should be included in the body of the report or in the patient's
31 chart. Comparison with the previous test results should be documented. This additional
32 documentation from the physician regarding the necessity for the additional repeat testing
33 would be appropriate. Repeat EDX testing should not be necessary in a 12-month period
34 in 80% of all cases.
35

36 The Professional Practice Committee of the AANEM developed the following
37 recommendations as part of the ABIM Choosing Wisely Initiative (AANEM, 2015):

- 38 • Don't do a needle electromyography (EMG) test for isolated neck or back pain after
39 a motor vehicle accident, as a needle EMG is unlikely to be helpful.
- 40 • Don't do a four limb needle EMG/nerve conduction study (NCS) testing for neck
41 and back pain after trauma.

- Don't do nerve conduction studies without also doing a needle EMG for testing for radiculopathy, a pinched nerve in the neck or back.

Sensitivity and specificity reports for electrodiagnostic testing methods (in general) vary. A clearly established measure of comparison is lacking in the medical literature, making comparisons across studies difficult. Some studies have compared results with clinical examination findings, imaging studies such as magnetic resonance imaging, computed tomography, myelography, or the observation of nerve root compression during surgery. Interobserver differences, the variety of tests employed, the presence of symptoms that may influence patient outcomes (e.g., pain), the presence of abnormal imaging studies in asymptomatic patients, and the subjectivity of the surgeon's interpretations may all lead to variances in sensitivity and specificity results. Despite these variances however, electrodiagnostic testing is commonly used to assist in diagnosing disorders involving the nerves, muscles and neuromuscular junction. Sensitivity and specificity data for automated/portable devices, used instead of or as an adjunct to standard nerve conduction testing, is insufficient to draw conclusions regarding predictive value.

DOCUMENTATION GUIDELINES

Documentation Required Justifying Electrodiagnostic Testing

- Reason for the study, clinical history and examination findings are required
- Numerical values are required – latency, amplitude and nerve conduction
- Type of needle – monopolar or concentric
- When documentation is required submit hard copy of waveforms and complete written report, including test interpretation
- Name, signature, professional designation of all individuals performing, interpreting or supervising the test must be included

Inadequate Documentation

- Narrative reports alluding to 'normal' or 'abnormal' results without numerical data
- Description of F-wave without reference to corresponding motor conduction data
- Pattern-setting unilateral H-reflex measurements
- Absence of clinical history, preferably written by the referral source, indicating the need for the test
- Absence of documentation to support repeat testing on the same beneficiary or testing every beneficiary referred for pain

Nerve conduction studies must provide a number of response parameters in a real-time fashion to facilitate provider interpretation. Those parameters include amplitude, latency, configuration and conduction velocity, temperature of limb. Diagnostic studies that do not provide this information or those that provide delayed interpretation as substitutes for nerve conduction studies are not accepted. Raw measurement data obtained and transmitted

1 trans-telephonically or over the Internet, therefore, does not qualify for the payment of the
2 electrodiagnostic service codes included in this policy.

3
4 Claims for nerve conduction testing accomplished with discriminatory devices that use
5 fixed anatomic templates and computer-generated reports used as an adjunct to physical
6 examination routinely on all patients are not accepted.

7
8 The AANEM provides specific recommendations for reporting needle EMG and NCV
9 results. According to the AANEM, the recommendation for documentation of nerve
10 conduction and EMG testing should include (but are not limited to) a description of the
11 patient's clinical problem (demographics, reason for referral), the electrodiagnostic tests
12 performed (techniques, distances, lab reference values, and temperature monitoring), all
13 relevant data derived from these tests (nerves/muscles tested, numerical values for latencies
14 and action potential), and the diagnostic interpretation of the data, including limitations.
15 Complete NCV test measurements should also include amplitude measurements, normal
16 reference values and criteria for abnormalities. The recommendations also include
17 confirmation that limb temperature was monitored continuously during the NCS and
18 repetitive stimulation and that (a) the hand temperature was maintained between 32°C and
19 36°C and (b) the foot temperature was maintained between 30°C and 36°C. NCS
20 abnormalities such as prolonged distal sensory or motor latencies could otherwise be due
21 to coolness of the limb. For repetitive stimulation, if the limb is not warmed, the results
22 may be assessed inaccurately as normal (AANEM, 2019).

23 24 **EVIDENCE REVIEW**

25 **Automated Nerve Conduction Testing**

26 Evidence evaluating the diagnostic utility of the Brevio and Virtual Medical Systems VT
27 3000 nerve conduction monitor systems (Automated Nerve Conduction Testing) is lacking.
28 Evidence evaluating the diagnostic utility of the NC-stat System consists mainly of case
29 series, case control studies and retrospective reviews. Some of these studies compare results
30 obtained using automated devices with results obtained from standard diagnostic testing
31 (NCV testing and EMG), other studies did not have a comparison to conventional testing.
32 Most of the published clinical studies have evaluated use of the NC-stat device for
33 assessment of median and ulnar nerves (Dale et al., 2015; Megerian et al., 2007; Kong et
34 al., 2006; Vinik et al., 2004); other published studies evaluated use of the device for
35 disorders such as lumbosacral radiculopathies (Fisher et al., 2008) and sensorimotor
36 polyneuropathy in diabetic patients (Perkins et al., 2008). In some of these studies a strong
37 correlation has been demonstrated when comparing NC-stat with reference standards
38 (Perkins et al., 2006; Kong et al., 2006). The diagnostic accuracy for other conditions, such
39 as those involving the lower extremities, has not been sufficiently demonstrated in the
40 literature. Data regarding diagnostic performance, sensitivity and specificity of the
41 automated NCV testing devices compared to standard testing is inconsistent and does not
42 lead to strong conclusions; the studies are not well-designed, involve small populations and

1 the results cannot be generalized. In some studies authors have reported high sensitivity
 2 and specificity when examining NC-stat accuracy for carpal tunnel syndrome compared to
 3 controls (Dale et al., 2015; Leffler et al., 2000; Rotman et al., 2004), other authors however
 4 have reported NC-stat is no more sensitive or specific than a traditionally performed distal
 5 motor latency for the diagnosis of carpal tunnel syndrome (Katz, 2006). In 2008,
 6 Armstrong and colleagues published the outcomes of a cohort study comparing the results
 7 obtained with the NC-stat device to traditional nerve conduction studies for carpal tunnel
 8 screening ($n=33$). All correlations were significant. The authors reported sensitivity, with
 9 respect to the traditional results, ranged from 93.8% to 100% and specificity ranged from
 10 84.6% to 94.1%. Nonetheless, the authors did not address limitations such as lack of needle
 11 EMG testing and did not evaluate the clinical relevance to the results (Armstrong et al.,
 12 2008). In a longitudinal study ($n=134$), Dale and colleagues (2015) compared automated
 13 nerve conduction using the NC Stat device to traditional electrodiagnostic studies for 62
 14 subjects, who had prior evaluation for carpal tunnel syndrome in the parent study ($n=780$).
 15 The authors reported that NC Stat results agreed with traditional electrodiagnostic studies
 16 for detecting median nerve conduction abnormalities within a general population of
 17 workers. Ulnar nerve testing results were not as favorable however median nerve testing
 18 results had high sensitivity and specificity (86-100%) for median motor and sensory
 19 latency. The study is limited by small sample population of industrial workers; results
 20 cannot be generalized to the standard population. A technology assessment conducted by
 21 the Washington State Department of Labor and Industries (2006) concluded that the
 22 scientific evidence does not show NC-stat to be equivalent to conventional methods for
 23 nerve conduction testing. Authors generally agree that further studies are needed to
 24 determine the role automated testing has as a component of clinical care. Furthermore,
 25 some concerns remain among specialists regarding lack of standard EMG testing and
 26 incomplete assessment when using automated NCV testing devices. The AANEM
 27 recommends electrodiagnostic studies be performed by properly trained physicians and
 28 that interpretation of nerve conduction study data alone, absent face-to-face patient
 29 interaction and control over the process, provides substandard care (AANEM, 2006). The
 30 AANEM (2010) does not support the following:

- 31 • Electrodiagnostic testing with automated, noninvasive nerve conduction testing
 32 devices
- 33 • Screening testing, monitoring disease intensity, or monitoring treatment efficacy
 34 for polyneuropathy of diabetes or polyneuropathy of end stage renal disease
 35 (ESRD)

36
 37 Schmidt and colleagues (2011) reported on the use of an automated hand-held nerve
 38 conduction device compared to NCS or needle electrode examination (standard
 39 electrodiagnostic tests) in the evaluation of individuals with unilateral leg symptoms. A
 40 total of 50 participants with complaints of unilateral leg pain, numbness or weakness were
 41 included in the study and underwent history with physical exam and standard
 42 electrodiagnostic testing. The participants were then tested using an automated hand-held

1 nerve conduction device. A total of 22 participants had findings consistent with
2 radiculopathy on standard electrodiagnostic test and 28 participants had a normal
3 electrodiagnostic exam or evidence of another distinct neuromuscular diagnosis. During
4 initial data analysis, a significant discrepancy was revealed between the results of standard
5 electrodiagnostic tests and the automated test. For this reason, another 25 participants were
6 recruited to serve as the control group. The control group participants had upper limb
7 symptoms such as cervical radiculopathy, carpal tunnel syndrome or ulnar neuropathy. Of
8 the 50 participants initially recruited, 28 were found to have normal standard
9 electrodiagnostic tests. The automated tests corroborated the findings in 4 cases only. In
10 the control group, all standard electrodiagnostic tests were normal, but the automated
11 testing showed 18 of 25 participants had findings consistent with radiculopathy or
12 polyneuropathy. Automated and standard testing correlated in 14 of 75 participants studied
13 (11 of whom had normal exams with both testing methods). While this study has a small
14 number of participants, the authors stated that "it is unlikely that larger study numbers
15 would have increased specificity to acceptable levels of a clinically useful test, given the
16 95% confidence levels for the current data."
17

18 In a position statement on the Proper Performance and Interpretation of Electrodiagnostic
19 Studies and the Recommended Use of Electrodiagnostic Medicine from the American
20 Association of Neuromuscular and Electrodiagnostic Medicine (AANEM, 2006, 2014,
21 2020), although no specific reference to or recommendation for automated nerve
22 conduction testing devices is made, it is noted that "Because needle EMG studies offer
23 information needed for an accurate diagnosis, except in unique situations, it is the
24 AANEM's position that NCSs and needle EMGs should be performed together in the same
25 setting." The document also notes that using only NCS may provide incomplete diagnostic
26 information which could lead to inadequate or inappropriate treatment. And: Individuals
27 without a medical education in neuromuscular disorders and without special training in
28 EDX procedures typically are not qualified to interpret the waveforms generated by NCSs
29 and needle EMGs or to correlate the findings with other clinical information to reach a
30 diagnosis. It is also the recommendation of the American Association of Neuromuscular
31 and Electrodiagnostic Medicine (AANEM) that electrodiagnostic testing/consultations are
32 conducted by physicians who have a comprehensive knowledge of neurological and
33 neuromusculoskeletal diseases, and in the application of neurophysiologic techniques for
34 evaluation of those disorders.
35

36 Although portable, automated, noninvasive testing of nerve conduction has been suggested
37 as an easier method for providers to obtain rapid results, the AANEM recommended that
38 EDX studies of EMG and NCS be performed "by physicians with medical education in
39 neuromuscular disorders and special training in EDX testing" (AANEM, 2020). Currently,
40 there is insufficient evidence in peer-reviewed published literature to demonstrate that
41 automated nerve conduction testing devices provide better measures in the diagnosis of
42 peripheral nerve disease. In addition, it remains unclear how testing with portable devices

1 improves clinical outcomes for populations such as diabetics compared to clinical detection
2 through neurological examination.

3
4 Since the clearance of the NC-stat, several other devices have also received FDA clearance
5 listing the NC-stat as the predicate device. However, to date there has been very limited
6 published evidence to demonstrate the safety and efficacy of automated, noninvasive nerve
7 conduction testing devices, as compared to conventional "gold standard" electrodiagnostic
8 testing using EMG and NCS. Most of the published clinical studies have evaluated use of
9 an automated device for assessment of the median and ulnar nerves only (Katz, 2006;
10 Kong, 2006).

11 **Other Electrodiagnostic Testing**

12 Evidence in the peer reviewed scientific literature including textbook and professional
13 society opinion supports clinical utility for electrodiagnostic testing, including
14 neuromuscular junction testing, when used to assist in diagnosing disorders involving the
15 nerves, muscles and neuromuscular junction. The AANEM has published guidance for the
16 performance of nerve conduction studies and EMG. According to the AANEM a typical
17 nerve conduction examination includes development of a differential diagnosis based upon
18 appropriate history and physical exam, the NCV study (recording and studying of electrical
19 responses from peripheral nerves or muscles) and the completion of indicated needle EMG
20 studies to evaluate the differential diagnosis and to complement the nerve conduction
21 study. In addition, the AANEM supports that when performing nerve conduction studies,
22 the waveform must be reviewed on site and in real time, with reports prepared onsite by
23 the examiner, consistent with current procedural terminology descriptions (AANEM,
24 2014). The AANEM defines the use of the term onsite as that where the history and
25 physical, performance of NCV and EMG, analysis of electrodiagnostic data and
26 determination of diagnosis occur in the same location, typically an electrodiagnostic
27 laboratory. Similarly, real time is defined as that which allows for information from the
28 physical and history to be integrated with the performance of testing, allowing for the
29 testing of both NCV and EMG to be tailored/modified to the individual circumstance as
30 needed before leaving the lab.
31

32
33 The use of nerve conduction studies including F-wave and H-reflex tests for the diagnosis
34 of early stage polyneuropathies and proximal nerve lesions is confirmed in several reviews
35 and studies (Choi and Maria, 2021; Maccabee et al., 2011; Kostera-Pruszczyk et al., 2004;
36 Trujillo-Hernandez et al., 2005; Bal et al., 2006; Kocer et al., 2005; Mesrati and
37 Vecchierini, 2004). The published scientific literature demonstrates somatosensory evoked
38 potential (SEP) studies are useful when used to aid in the diagnosis of various
39 neuromuscular disorders and have varying degrees of sensitivity and specificity.
40

41 Nerve conduction studies are indicated for the following conditions: peripheral nerve
42 entrapment (Omejec, 2014; Park, 2014; Calfee, 2012; Kwon, 2008; Vij et al., 2021);

1 generalized neuropathies (Choi and Maria, 2021; Holiner, 2013; Derr, 2009; Dyck, 2010;
 2 De Sousa, 2009); polyneuropathies (Choi and Maria, 2021; de Souza, 2015; Emeryk-
 3 Szajewska, 1998; Torvin Moller, 2009); plexopathy (Mullins, 2007); neuromuscular
 4 junction disorders (Meriggioli, 2005); myopathies including polymyositis,
 5 dermatomyositis, and congenital myopathies (Wang, 2010); motor neuron disease
 6 (Hammad, 2007); spine disorders and radiculopathy (Pawar, 2013; Alrawi, 2007; Haig,
 7 2006); and guidance for botulinum toxin injection for spasmodic dysphonia or segmental
 8 dystonia, when it is difficult to isolate affected muscles (Molloy, 2002).

9
 10 Karami-Mohajeri et al. (2014) presented a systematic review of the recent literature on the
 11 scientific support of EMG and NCV in diagnosing the exposure and toxicity of
 12 organophosphorus pesticides (OP). Specifically, this review focused on changes in EMG,
 13 NCV, occurrence of intermediate syndrome (IMS), and OP-induced delayed
 14 polyneuropathy (OPIDN) in human. All relevant bibliographic databases were searched
 15 for human studies using the key words "OP poisoning", "electromyography", "nerve
 16 conduction study," and "muscles disorders". Intermediate syndrome usually occurs after
 17 an acute cholinergic crisis, while OPIDN occurs after both acute and chronic exposures.
 18 Collection of these studies supported that IMS is a neuromuscular junction disorder and
 19 can be recorded upon the onset of respiratory failure. Due to heterogeneity of reports on
 20 outcomes of interest such as motor NCV and EMG amplitude in acute cases and inability
 21 to achieve precise estimation of effect in chronic cases meta-analysis was not helpful to
 22 this review. The OPIDN after both acute and low-level prolonged exposures develops
 23 peripheral neuropathy without preceding cholinergic toxicity and the progress of changes
 24 in EMG and NCV is parallel with the development of IMS and OPIDN. Persistent
 25 inhibition of acetylcholinesterase (AChE) is responsible for muscle weakness, but this is
 26 not the only factor involved in the incidence of this weakness in IMS or OPIDN suggestive
 27 of AChE assay not useful as an index of nerve and muscle impairment. The authors
 28 concluded that although several mechanisms for induction of this neurodegenerative
 29 disorder have been proposed, among them oxidative stress and resulting apoptosis can be
 30 emphasized. Nevertheless, they stated that there is little synchronized evidence on
 31 subclinical electrophysiological findings that limit these investigators to reach a strong
 32 conclusion on the diagnostic or prognostic use of EMG and NCV for acute and
 33 occupational exposures to OPs.

34
 35 Asad et al. (2009) compared the nerve conduction studies in clinically undetectable and
 36 detectable sensorimotor polyneuropathy in type 2 diabetics. Diagnosed diabetics ($n = 60$)
 37 were divided in two groups. Group 1 ($n 1 = 30$) with clinically undetectable and group 2
 38 ($n 2 = 30$) with clinically detectable Diabetic Polyneuropathy. Detection of the
 39 sensorimotor neuropathy was done according to Diabetic Neuropathy Symptom Score and
 40 Diabetic Neuropathy Examination scores. The simplified nerve conduction studies
 41 protocol was followed in recording amplitudes, velocities and latencies of minimum two
 42 (Sural, Peroneal) and maximum six i.e., three sensory (Sural, Ulnar, Median) and three

1 motor (Peroneal, Ulnar, Tibial) nerves. The comparisons were done between different
 2 parameters of nerve conduction studies with the neurological scores in undetectable and
 3 detectable groups using Pearson's chi square test. The amplitudes, velocities, latencies,
 4 outcome and grading of neuropathy in nerve conduction studies when compared with
 5 neurological detection scores showed a significant relation in each group regarding
 6 evaluation ($p = 0.005$, $p = 0.004$, $p = 0.05$, $p = 0.00001$, $p = 0.003$ respectively). Diabetic
 7 Neuropathy Symptom Score and Diabetic Neuropathy Examination Score together can
 8 help in prompt evaluation of the diabetic sensorimotor polyneuropathy though nerve
 9 conduction study is more powerful test and can help in diagnosing subclinical cases.

10 **Surface Electromyography (SEMG)**

11 There is a wide variety of Surface Electromyography (SEMG) hardware and software that
 12 is used depending upon the specific clinical purpose intended. However, all SEMG
 13 hardware and software have in common the following:
 14

- 15 • Electrical signals are measured from skeletal muscles.
- 16 • Sensing electrodes are placed on the skin overlying the muscle of interest.
- 17 • The electrical activity is measured when the muscle is active.
- 18 • SEMG records a narrow frequency of electrical activity (20-500 Hz).
- 19 • SEMG findings are based on computer analysis of either the frequency spectrum
 20 (spectral analysis), amplitude of signal, or root mean square of electrical action
 21 potentials.

22 **The Evaluation of Specific Neuromuscular Pathologies**

23 The literature on the subject of SEMG use for neuromuscular disorders indicates that it is
 24 inferior in all parameters (sensitivity, specificity, spatial resolution, signal to noise ratio) to
 25 the invasive procedures such as needle electromyography (NEMG) or fine-wire
 26 electromyography (FWEMG) and thus cannot be used as a substitute for those procedures.
 27 Both systematic reviews of this subject explicitly reject SEMG for the diagnosis of
 28 neuromuscular disease.
 29

30
 31 The gold standard for this type of evaluation is either NEMG or FWEMG. Because these
 32 procedures are both invasive and painful, there is an obvious desire to find equally useful,
 33 but less onerous diagnostic tests. There are, however, several inherent limitations to the use
 34 of SEMG for the analysis of neuromuscular pathology. SEMG records input from a much
 35 wider spatial field than do either of the invasive procedures. Muscles adjacent to those of
 36 interest can produce signals that appear to originate from the target muscles (which are
 37 located immediately beneath the sensing electrodes). Thus, the specificity of SEMG
 38 findings is always in doubt. SEMG is also very susceptible to movement artifact. Even
 39 with the most careful procedural safeguards, small (and even imperceptible) body
 40 movements may produce spurious signals. There is a much poorer signal to noise ratio with
 41 SEMG. This is particularly a problem when target muscles are located more than 10 mm
 42 below the skin surface. Finally, the electrical activity that is recorded by SEMG is only of

1 skeletal muscle origins. It is not possible to capture any electrical activity along motor
2 neuron axons, as it is with NEMG or FWEMG.

4 **The Evaluation of Movement and Gait Disturbances**

5 There are a variety of experimental applications such as studies of human movement, the
6 study of nerve conduction velocities after electrical stimulation of peripheral nerves, etc.,
7 in which SEMG is considered standard. Because of its relative ease of use and non-invasive
8 nature, SEMG is considered superior to NEMG and FWEMG for many of these
9 applications. There are also thought to be advantages in using SEMG to evaluate/study
10 movement disorders of CNS origins such as tremor, dystonia, dyskinesia, and myoclonus.
11 While it is thought that SEMG can accurately measure these disorders, it is less clear what
12 the clinical utility of these measurements might be. This is the only application for which
13 the American Medical Association (AMA) Current Procedural Terminology (CPT) coding
14 committee has developed a procedure code.

16 **The Evaluation of Functional Back Pain**

17 There are a number of studies that have investigated the possibility that SEMG may
18 differentiate between those with and those without back pain by evaluating muscle fatigue
19 through “spectral shift”. However, the findings are inconsistent and contradictory, the
20 relationship between muscle fatigue and back pain is not established, and there may be
21 unrelated factors affecting spectral shift.

22
23 The clinical context in which chiropractors are most likely to use SEMG is for the
24 evaluation of functional low back pain and neck pain. There are two proposed mechanisms
25 by which SEMG is thought to relate to back pain. First is the presumed relationship
26 between muscle fatigue and back pain. The theory posits that excessive muscle fatigue, due
27 to deconditioning, may result in back pain. Further, it has been shown that when muscles
28 fatigue they produce a different set of electrical frequencies as measured by SEMG. This
29 phenomenon has been dubbed the “spectral shift.” Thus, it has been hypothesized that by
30 using dynamic SEMG (recording muscle activity while exercising) it should be possible to
31 differentiate those with back pain from those without back pain. There are a number of
32 studies that have investigated this possibility, and some have had success in doing so.
33 However, this success is tempered by several caveats. First, these findings are inconsistent
34 and somewhat contradictory. Second, the exact nature of the relationship between muscle
35 fatigue and back pain is uncertain. In fact, the direction of the relationship is uncertain—
36 does muscle fatigue cause back pain or does back pain cause muscle fatigue? Third, it is
37 unclear what other factors might cause a spectral shift making the specificity of such
38 findings doubtful.

39
40 There is another mechanism by which it is proposed that SEMG can assist in the evaluation
41 of back pain: the identification of hypertonic muscles. It is this mechanism that the leading
42 chiropractic proponents of SEMG suggest is the most relevant to patient management. In

1 effect, it is proposed that SEMG is a more objective and accurate tool than palpation in
2 locating hypertonic muscles and thereby the identification of vertebral subluxations. The
3 literature relative to this mechanism is even more limited and of much poorer quality than
4 is the literature on muscle fatigue and SEMG. It is also speculated that the finding of SEMG
5 asymmetry is an indication of spinal dysfunction. There is no literature that finds a
6 relationship between back pain and such asymmetry and at least one study that casts doubt
7 on this hypothesis. SEMG is not reliable for assessing spinal dysfunction or subluxation.
8

9 A recent analysis by Triano et al. (2013) examined the techniques and procedures used by
10 chiropractors to identify the appropriate site for the application of spinal manipulation.
11 Consistent with previous reviews they found limited support for reliability of SEMG to
12 identify cohorts of patients with abnormal neuromuscular control. However, the review
13 concluded that there was no support for the use of SEMG to localize treatment to a specific
14 site. Another area of research for SEMG is its use as a prognostic tool. Studies have looked
15 at flexion and extension movements to determine the prognosis of the patient relative to
16 their low back pain recovery. Hu et al. (2014) evaluated the prognostic value of quantitative
17 SEMG topographic analysis and attempted to verify the accuracy of the performance of
18 proposed time-varying topographic parameters for identifying the patients who have better
19 response toward the rehabilitation program. Thirty-eight patients with chronic nonspecific
20 LBP and 43 healthy subjects were included in the study. These patients suffered from
21 chronic nonspecific LBP without the history of back surgery and any medical conditions
22 causing acute exacerbation of LBP during the clinical test were enlisted to perform the
23 clinical test during the 12-week physiotherapy (PT) treatment. Low back pain patients were
24 classified into two groups: "responding" and "nonresponding" based on the clinical
25 assessment. The responding group referred to the LBP patients who began to recover after
26 the PT treatment, whereas the nonresponding group referred to some LBP patients who did
27 not recover or got worse after the treatment. The quantitative time-varying analysis of
28 SEMG topography showed significant difference between the healthy and LBP groups.
29 The discrepancies in quantitative dynamic SEMG topography of LBP group from normal
30 group, were able to identify those LBP subjects who would respond to a conservative
31 rehabilitation program focused on functional restoration of lumbar muscle. More research
32 is needed to confirm results and evaluate its utility clinically.
33

34 In assessing the appropriateness of SEMG for functional back pain, there are three levels
35 of analysis to consider that remain pertinent:

- 36 1. **Technical performance of the instrument.** To what extent does the instrument
37 accurately measure what it purports to measure (e.g., muscle fatigue, muscle
38 spasm)? The above discussion regarding neuromuscular disorders identifies several
39 inherent limitations in the technical performance of SEMG. All of those limitations
40 (with the exception of the inability to measure axonal signals) are relevant to this
41 issue as well. The lack of specificity, poor signal to noise ratio, and the problem of

1 movement artifacts will all limit the accuracy and validity of SEMG for the
 2 evaluation of functional back pain.

3
 4 **2. Whether and how the instrument findings can be used in patient management.**

5 The use of SEMG as a “subluxation detector” that can help identify specific levels
 6 of spinal dysfunction has not been substantiated and is entirely speculative.

7
 8 If it has been determined that it is possible to identify hypo- or hypertonic muscles
 9 through the use of SEMG (keeping in mind the inherent technical limitations
 10 affecting specificity, accuracy, and validity), the question becomes how this
 11 information will be used in the management of the patient. To date, the only clinical
 12 correlation that has been established is that there *may* be differences between
 13 subjects with back pain and control subjects in their muscle fatigability as measured
 14 by SEMG. In other words, it may be possible to differentiate those with and without
 15 back pain using SEMG. But as one of the systematic reviews points out, the gold
 16 standard for the presence or absence of back pain is the clinical history, and it is far
 17 easier and more reliable to simply ask the person whether he or she has back pain.
 18 While potentially, it might be possible to use SEMG to identify malingerers, the
 19 procedure is currently far too unreliable to permit any such determination to be
 20 predicated on SEMG findings. In addition, several established malingering tests are
 21 available as taught within standard orthopedic examination courses in chiropractic,
 22 osteopathic, and medical schools.

23
 24 **3. Whether the use of an instrument results in better clinical outcomes.** There is
 25 no evidence (and very little theory) to indicate how specific SEMG findings should
 26 be used to manage individuals with back pain in order to produce better clinical
 27 outcomes.

28
 29 Ultimately what matters is whether or not the use of SEMG results in better clinical
 30 outcomes than does the management of back pain without the use of SEMG
 31 information. There have been no clinical trials that have addressed this question. In
 32 fact, there are no clinical trials of back pain that have used SEMG in any aspect of
 33 the diagnosis of subjects, in measuring outcomes of treatment, or otherwise
 34 evaluating the effectiveness of the therapeutic intervention (e.g., chiropractic
 35 treatment).

36
 37 **PRACTITIONER SCOPE AND TRAINING**

38 Practitioners should practice only in the areas in which they are competent based on their
 39 education, training and experience. Levels of education, experience, and proficiency may
 40 vary among individual practitioners. It is ethically and legally incumbent on a practitioner
 41 to determine where they have the knowledge and skills necessary to perform such services
 42 and whether the services are within their scope of practice.

1 It is best practice for the practitioner to appropriately render services to a member only if
 2 they are trained, equally skilled, and adequately competent to deliver a service compared
 3 to others trained to perform the same procedure. If the service would be most competently
 4 delivered by another health care practitioner who has more skill and training, it would be
 5 best practice to refer the member to the more expert practitioner.

6
 7 Best practice can be defined as a clinical, scientific, or professional technique, method, or
 8 process that is typically evidence-based and consensus driven and is recognized by a
 9 majority of professionals in a particular field as more effective at delivering a particular
 10 outcome than any other practice (Joint Commission International Accreditation Standards
 11 for Hospitals, 2020).

12
 13 Depending on the practitioner’s scope of practice, training, and experience, a member’s
 14 condition and/or symptoms during examination or the course of treatment may indicate the
 15 need for referral to another practitioner or even emergency care. In such cases it is prudent
 16 for the practitioner to refer the member for appropriate co-management (e.g., to their
 17 primary care physician) or if immediate emergency care is warranted, to contact 911 as
 18 appropriate. See the *Managing Medical Emergencies (CPG 159 – S)* clinical practice
 19 guideline for information.

20 21 **References**

22 AANEM. AANEM's top five choosing wisely recommendations. *Muscle Nerve*.
 23 2015;51(4):617-619. doi:10.1002/mus.24628

24
 25 Ahern DK, Follick MJ, Council JR, Laser-Wolston N. Reliability of lumbar paravertebral
 26 EMG assessment in chronic low back pain. *Arch Phys Med Rehabil*. 1986;67(10):762-
 27 765. doi:10.1016/0003-9993(86)90014-6

28
 29 Ahern DK, Follick MJ, Council JR, Laser-Wolston N, Litchman H. Comparison of lumbar
 30 paravertebral EMG patterns in chronic low back pain patients and non-patient
 31 controls. *Pain*. 1988;34(2):153-160. doi:10.1016/0304-3959(88)90160-1

32
 33 Alemo S, Sayadipour A. Role of intraoperative neurophysiologic monitoring in
 34 lumbosacral spine fusion and instrumentation: a retrospective study. *World Neurosurg*.
 35 2010;73(1):72-e7. doi:10.1016/j.surneu.2009.04.024

36
 37 Alexiev AR. Some differences of the electromyographic erector spinae activity between
 38 normal subjects and low back pain patients during the generation of isometric trunk
 39 torque. *Electromyogr Clin Neurophysiol*. 1994;34(8):495-499

- 1 Alrawi MF, Khalil NM, Mitchell P, Hughes SP. The value of neurophysiological and
2 imaging studies in predicting outcome in the surgical treatment of cervical
3 radiculopathy. *Eur Spine J.* 2007;16(4):495-500. doi:10.1007/s00586-006-0189-6
4
- 5 Al-Shekhlee A, Shapiro BE, Preston DC. Iatrogenic complications and risks of nerve
6 conduction studies and needle electromyography. *Muscle Nerve.* 2003;27(5):517-526.
7 doi:10.1002/mus.10315
8
- 9 Ambroz C, Scott A, Ambroz A, Talbott EO. Chronic low back pain assessment using
10 surface electromyography. *J Occup Environ Med.* 2000;42(6):660-669.
11 doi:10.1097/00043764-200006000-00018
12
- 13 American Academy of Neurology (AAN). Position statement. Mobile electrodiagnostic
14 laboratories provide substandard patient care. 2015. Updated and reapproved August
15 2020. Retrieved on July 3, 2023 from [https://www.aanem.org/clinical-practice-
16 resources/position-statements/position-statement/mobile-electrodiagnostic-
17 laboratories-provide-substandard-patient-care](https://www.aanem.org/clinical-practice-resources/position-statements/position-statement/mobile-electrodiagnostic-laboratories-provide-substandard-patient-care)
18
- 19 American Academy of Neurology (AAN). Principles of coding for intraoperative
20 neurophysiologic monitoring (IOM) and testing model medical policy. 2012. Retrieved
21 on July 3, 2023 from [https://www.aan.com/siteassets/home-page/tools-and-
22 resources/practicing-neurologist--administrators/billing-and-coding/model-coverage-
23 policies/16iommodelpolicy_tr.pdf](https://www.aan.com/siteassets/home-page/tools-and-resources/practicing-neurologist--administrators/billing-and-coding/model-coverage-policies/16iommodelpolicy_tr.pdf)
24
- 25 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM).
26 Definition of real time onsite. Position Statement. July 2014. Retrieved on July 1, 2023
27 from [https://www.aanem.org/clinical-practice-resources/position-statements/position-
28 statement/definition-of-real-time-onsite](https://www.aanem.org/clinical-practice-resources/position-statements/position-statement/definition-of-real-time-onsite)
29
- 30 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM).
31 Model Policy for Nerve Conduction Studies and Needle Electromyography 2016.
32 Retrieved on June 30, 2023 from [https://www.aanem.org/clinical-practice-
33 resources/position-statements/position-statement/model-policy-for-nerve-conduction-
34 studies-and-needle-electromyography](https://www.aanem.org/clinical-practice-resources/position-statements/position-statement/model-policy-for-nerve-conduction-studies-and-needle-electromyography)
35
- 36 American Association of Neuromuscular & Electrodiagnostic Medicine. Needle EMG in
37 certain uncommon clinical contexts. *Muscle Nerve.* 2005;31(3):398-399.
38 doi:10.1002/mus.20238
39
- 40 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM).
41 Position Statement. Reporting the results of needle EMG and nerve conduction studies:
42 and educational report. May 2014. Updated and reapproved July 2018. Retrieved on

1 July 3, 2023 from: <https://www.aanem.org/clinical-practice-resources/position-statements/position-statement/reporting-the-results-of-nerve-conduction-studies-and-needle-emg>

2
3
4
5 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM).
6 Position Statement. Technologist Performance Of Nerve Conduction Studies And
7 Somatosensory Evoked Potentials Under Direct Edx Physician Supervision. Approved
8 by the American Association of Electrodiagnostic Medicine May 1999b. Modified and
9 approved August 2020. Retrieved on July 3, 2023 from
10 [https://www.aanem.org/docs/default-](https://www.aanem.org/docs/default-source/documents/aanem/advocacy/technologists-conducting-ncs_sep_2020.pdf?sfvrsn=132d3dd3_3)
11 [source/documents/aanem/advocacy/technologists-conducting-](https://www.aanem.org/docs/default-source/documents/aanem/advocacy/technologists-conducting-ncs_sep_2020.pdf?sfvrsn=132d3dd3_3)
12 [ncs_sep_2020.pdf?sfvrsn=132d3dd3_3](https://www.aanem.org/docs/default-source/documents/aanem/advocacy/technologists-conducting-ncs_sep_2020.pdf?sfvrsn=132d3dd3_3)
13

14 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM).
15 Practice parameter for Repetitive Nerve Stimulation & Single Fiber EMG Evaluation
16 of Adults w/Suspected Myasthenia Gravis. Reaffirmed October 2015. Retrieved on
17 July 3, 2023 from [https://www.aanem.org/clinical-practice-](https://www.aanem.org/clinical-practice-resources/guidelines/guideline/practice-parameter-for-rns-and-single-fiber-emg-eval-of-adults-with-suspected-mg)
18 [resources/guidelines/guideline/practice-parameter-for-rns-and-single-fiber-emg-eval-](https://www.aanem.org/clinical-practice-resources/guidelines/guideline/practice-parameter-for-rns-and-single-fiber-emg-eval-of-adults-with-suspected-mg)
19 [of-adults-with-suspected-mg](https://www.aanem.org/clinical-practice-resources/guidelines/guideline/practice-parameter-for-rns-and-single-fiber-emg-eval-of-adults-with-suspected-mg)
20

21 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM).
22 Proper performance and interpretation of electrodiagnostic studies. Muscle Nerve.
23 2006 Mar;33(3):436-9. Reviewed and updated Jan 2020. Retrieved on July 3, 2023
24 from [https://www.aanem.org/clinical-practice-resources/position-statements/position-](https://www.aanem.org/clinical-practice-resources/position-statements/position-statement/proper-performance-and-interpretation-of-electrodiagnostic-studies)
25 [statement/proper-performance-and-interpretation-of-electrodiagnostic-studies](https://www.aanem.org/clinical-practice-resources/position-statements/position-statement/proper-performance-and-interpretation-of-electrodiagnostic-studies)
26

27 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM).
28 (2020). Risks in electrodiagnostic medicine. Retrieved on July 3, 2023 from
29 [https://www.aanem.org/clinical-practice-resources/position-statements/position-](https://www.aanem.org/clinical-practice-resources/position-statements/position-statement/risks-in-electrodiagnostic-medicine)
30 [statement/risks-in-electrodiagnostic-medicine](https://www.aanem.org/clinical-practice-resources/position-statements/position-statement/risks-in-electrodiagnostic-medicine)
31

32 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM).
33 Somatosensory evoked potentials. Clinical uses. Chapter 5. Muscle Nerve 22:
34 Supplement 8: S111-S118, 1999a. Retrieved on July 3, 2023 from
35 [https://www.aanem.org/clinical-practice-](https://www.aanem.org/clinical-practice-resources/guidelines/guideline/somatosensory-evoked-potentials-clinical-uses)
36 [resources/guidelines/guideline/somatosensory-evoked-potentials-clinical-uses](https://www.aanem.org/clinical-practice-resources/guidelines/guideline/somatosensory-evoked-potentials-clinical-uses)
37

38 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM). Who
39 is qualified to practice electrodiagnostic medicine. Position statement. Updated and Re-
40 approved: May 2012; November 2017 Retrieved on July 3, 2023 from
41 [https://www.aanem.org/clinical-practice-resources/position-statements/position-](https://www.aanem.org/clinical-practice-resources/position-statements/position-statement/who-is-qualified-to-practice-electrodiagnostic-medicine)
42 [statement/who-is-qualified-to-practice-electrodiagnostic-medicine](https://www.aanem.org/clinical-practice-resources/position-statements/position-statement/who-is-qualified-to-practice-electrodiagnostic-medicine)

- 1 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM).
 2 Model Policy for Nerve Conduction Studies and Needle Electromyography. Updated
 3 and reapproved Dec 2022. Retrieved on July 3, 2023 from
 4 [https://www.aanem.org/clinical-practice-resources/position-statements/position-](https://www.aanem.org/clinical-practice-resources/position-statements/position-statement/model-policy-for-nerve-conduction-studies-and-needle-electromyography)
 5 [statement/model-policy-for-nerve-conduction-studies-and-needle-electromyography](https://www.aanem.org/clinical-practice-resources/position-statements/position-statement/model-policy-for-nerve-conduction-studies-and-needle-electromyography)
 6
- 7 American Clinical Neurophysiology Society (ACNS). Guidelines for short latency
 8 somatosensory evoked potentials. Feb 10, 2006. Retrieved on July 3, 2023 from
 9 <https://www.acns.org/practice/guidelines>
 10
- 11 American Medical Association. (current year) Current Procedural Terminology (CPT)
 12 Current year (rev. ed.), Chicago: AMA.
 13
- 14 American Society of Electroneurodiagnostic Technologists (ASET). National competency
 15 skill standards for performing Intraoperative neurophysiologic monitoring . Retrieved
 16 on July 3, 2023 from [https://www.aset.org/wp-](https://www.aset.org/wp-content/uploads/2022/01/IONM_National_Competency_Skill_Standards_Approved_2011.pdf)
 17 [content/uploads/2022/01/IONM_National_Competency_Skill_Standards_Approved_](https://www.aset.org/wp-content/uploads/2022/01/IONM_National_Competency_Skill_Standards_Approved_2011.pdf)
 18 [2011.pdf](https://www.aset.org/wp-content/uploads/2022/01/IONM_National_Competency_Skill_Standards_Approved_2011.pdf)
 19
- 20 American Society of Neurophysiological Monitoring (ASNM). Intraoperative monitoring
 21 using somatosensory evoked potentials. A position statement by the American Society
 22 of Neurophysiological Monitoring. *J Clin Monit Comput.* 2005 Jun;24:1-58 (18).
 23
- 24 American Speech-Language-Hearing Association. Neurophysiologic Intraoperative
 25 Monitoring. Position Statement. Copyright©2013 American Language-Speech-
 26 Hearing Association. Retrieved on July 3, 2023 from
 27 <http://www.asha.org/policy/PS1992-00036/>
 28
- 29 Aminoff MJ, Eisen A. Somatosensory Evoked Potentials. In: Aminoff's Electrodiagnosis
 30 in Clinical Neurology. Ch 26. Sixth Edition © 2012, Elsevier Inc.
 31
- 32 Aminoff MJ. Electrophysiologic testing for the diagnosis of peripheral nerve
 33 injuries. *Anesthesiology.* 2004;100(5):1298-1303. doi:10.1097/00000542-200405000-
 34 [00034](https://doi.org/10.1097/00000542-200405000-00034).
 35
- 36 Armstrong TN, Dale AM, Al-Lozi MT, Franzblau A, Evanoff BA. Median and ulnar nerve
 37 conduction studies at the wrist: criterion validity of the NC-stat automated device. *J*
 38 *Occup Environ Med.* 2008;50(7):758-764. doi:10.1097/JOM.0b013e3181645425
 39
- 40 Asad A, Hameed MA, Khan UA, Butt MU, Ahmed N, Nadeem A. Comparison of nerve
 41 conduction studies with diabetic neuropathy symptom score and diabetic neuropathy

1 examination score in type-2 diabetics for detection of sensorimotor polyneuropathy. J
2 Pak Med Assoc. 2009;59(9):594-598.

3
4 Asbury AK. Approach to the patient with peripheral neuropathy. In: Harrison's Principles
5 of Internal Medicine. Part 15: Neurologic disorders. Section 3: Nerve and muscle
6 disorders. Chapter 363. Electrodiagnosis. Copyright 2004 by The McGraw-Hill
7 Companies, Inc.

8
9 Assessment: dermatomal somatosensory evoked potentials. Report of the American
10 Academy of Neurology's Therapeutics and Technology Assessments
11 Subcommittee. Neurology. 1997;49(4):1127-1130.

12
13 Assessment: intraoperative neurophysiology. Report of the Therapeutics and Technology
14 Assessment Subcommittee of the American Academy of Neurology. Neurology.
15 1990;40(11):1644-1646.

16
17 Bal S, Celiker R, Palaoglu S, Cila A. F wave studies of neurogenic intermittent claudication
18 in lumbar spinal stenosis. Am J Phys Med Rehabil. 2006;85(2):135-140.
19 doi:10.1097/01.phm.0000197586.91860.a1

20
21 Barboi AC, Barkhaus PE. Electrodiagnostic testing in neuromuscular disorders. Neurol
22 Clin. 2004;22(3):619-vi. doi:10.1016/j.ncl.2004.03.007

23
24 Biedermann HJ, Shanks GL, Forrest WJ, Inglis J. Power spectrum analyses of
25 electromyographic activity. Discriminators in the differential assessment of patients
26 with chronic low-back pain. Spine (Phila Pa 1976). 1991;16(10):1179-1184.

27
28 Bollu, PC. Single-fiber EMG. eMedicine Specialties. Neurology. Electromyography and
29 Nerve Conduction Studies. Updated March 2019. Retrieved on July 1, 2023 from
30 <http://www.emedicine.com/neuro/topic343.htm>

31
32 Bose B, Wierzbowski LR, Sestokas AK. Neurophysiologic monitoring of spinal nerve root
33 function during instrumented posterior lumbar spine surgery. Spine (Phila Pa 1976).
34 2002;27(13):1444-1450. doi:10.1097/00007632-200207010-00014

35
36 Braunwald: Harrison's Principles of Internal Medicine. Electrophysiology studies of
37 muscle and nerve: Electrophysiologic studies of the central and peripheral nervous
38 systems. ©2001, The McGraw-Hill Companies, Inc. Chapter 357.

39
40 Calfee RP, Dale AM, Ryan D, Descatha A, Franzblau A, Evanoff B. Performance of
41 simplified scoring systems for hand diagrams in carpal tunnel syndrome screening. J
42 Hand Surg Am. 2012;37(1):10-17. doi:10.1016/j.jhsa.2011.08.016

- 1 Chang MH, Liu LH, Lee YC, Wei SJ, Chiang HL, Hsieh PF. Comparison of sensitivity of
2 transcarpal median motor conduction velocity and conventional conduction techniques
3 in electrodiagnosis of carpal tunnel syndrome. *Clin Neurophysiol.* 2006;117(5):984-
4 991. doi:10.1016/j.clinph.2006.01.015
5
- 6 Chawla J, Burneo JG, Barkley GL. Clinical Applications of Somatosensory Evoked
7 Potentials. Medscape. Updated Aug 2019. Retrieved on July 3, 2023 from
8 <http://emedicine.medscape.com/article/1139393-overview#showall>
9
- 10 Chiappa K. Electrophysiologic monitoring during carotid endarterectomies. In: Chiappa
11 K, editor. *Evoked potentials in clinical medicine*. Third edition. ©1997. Lippincott-
12 Raven Publishers. Philadelphia –New York. Ch. 19.
13
- 14 Chiappa K, Cros D. Dermatomal somatosensory evoked potentials. In: Chiappa K, editor.
15 *Evoked potentials in clinical medicine*. Third edition. ©1997. Lippincott-Raven
16 Publishers. Philadelphia –New York. Ch. 12.
17
- 18 Cho SC, Ferrante MA, Levin KH, Harmon RL, So YT. Utility of electrodiagnostic testing
19 in evaluating patients with lumbosacral radiculopathy: An evidence-based
20 review. *Muscle Nerve.* 2010;42(2):276-282. doi:10.1002/mus.21759
21
- 22 Choi JM, Di Maria G. Electrodiagnostic Testing for Disorders of Peripheral Nerves. *Clin*
23 *Geriatr Med.* 2021;37(2):209-221. doi:10.1016/j.cger.2021.01.010
24
- 25 Collins GA, Cohen MJ, Naliboff BD, Schandler SL. Comparative analysis of paraspinal
26 and frontalis EMG, heart rate and skin conductance in chronic low back pain patients
27 and normals to various postures and stress. *Scand J Rehabil Med.* 1982;14(1):39-46..
28
- 29 Cruccu G, Aminoff MJ, Curio G, et al. Recommendations for the clinical use of
30 somatosensory-evoked potentials. *Clin Neurophysiol.* 2008;119(8):1705-1719.
31 doi:10.1016/j.clinph.2008.03.016
32
- 33 Crum BA, Strommen JA. Peripheral nerve stimulation and monitoring during operative
34 procedures. *Muscle Nerve.* 2007;35(2):159-170. doi:10.1002/mus.20707
35
- 36 Dale AM, Agboola F, Yun A, Zeringue A, Al-Lozi MT, Evanoff B. Comparison of
37 automated versus traditional nerve conduction study methods for median nerve testing
38 in a general worker population. *PM R.* 2015;7(3):276-282.
39 doi:10.1016/j.pmrj.2014.10.003

- 1 Danneels LA, Cagnie BJ, Cools AM, et al. Intra-operator and inter-operator reliability of
 2 surface electromyography in the clinical evaluation of back muscles. *Man Ther.*
 3 2001;6(3):145-153. doi:10.1054/math.2001.0396
 4
- 5 DeGood DE, Stewart WR, Adams LE, Dale JA. Paraspinal EMG and autonomic reactivity
 6 of patients with back pain and controls to personally relevant stress. *Percept Mot Skills.*
 7 1994;79(3 Pt 1):1399-1409. doi:10.2466/pms.1994.79.3.1399.
 8
- 9 Derr JJ, Micklesen PJ, Robinson LR. Predicting recovery after fibular nerve injury: which
 10 electrodiagnostic features are most useful?. *Am J Phys Med Rehabil.* 2009;88(7):547-
 11 553. doi:10.1097/PHM.0b013e3181a9f519
 12
- 13 De Sousa EA, Chin RL, Sander HW, Latov N, Brannagan TH 3rd. Demyelinating findings
 14 in typical and atypical chronic inflammatory demyelinating polyneuropathy: sensitivity
 15 and specificity. *J Clin Neuromuscul Dis.* 2009;10(4):163-169.
 16 doi:10.1097/CND.0b013e31819a71e1
 17
- 18 de Souza RJ, de Souza A, Nagvekar MD. Nerve conduction studies in diabetics
 19 presymptomatic and symptomatic for diabetic polyneuropathy. *J Diabetes*
 20 *Complications.* 2015;29(6):811-817. doi:10.1016/j.jdiacomp.2015.05.009
 21
- 22 Devlin VJ, Schwartz DM. Intraoperative neurophysiologic monitoring during spinal
 23 surgery. *J Am Acad Orthop Surg.* 2007;15(9):549-560. doi:10.5435/00124635-
 24 200709000-00005
 25
- 26 Drost G, Stegeman DF, van Engelen BG, Zwarts MJ. Clinical applications of high-density
 27 surface EMG: a systematic review. *J Electromyogr Kinesiol.* 2006;16(6):586-602.
 28 doi:10.1016/j.jelekin.2006.09.005
 29
- 30 Dyck PJ, Overland CJ, Low PA, et al. Signs and symptoms versus nerve conduction studies
 31 to diagnose diabetic sensorimotor polyneuropathy: CI vs. NPhys trial. *Muscle Nerve.*
 32 2010;42(2):157-164. doi:10.1002/mus.21661
 33
- 34 Eager M, Shimer A, Jahangiri FR, Shen F, Arlet V. Intraoperative neurophysiological
 35 monitoring (IONM): lessons learned from 32 case events in 2069 spine cases. *Am J*
 36 *Electroneurodiagnostic Technol.* 2011;51(4):247-263.
 37
- 38 Edwards BM, Kileny PR. Intraoperative neurophysiologic monitoring: indications and
 39 techniques for common procedures in otolaryngology-head and neck
 40 surgery. *Otolaryngol Clin North Am.* 2005;38(4):631-viii.
 41 doi:10.1016/j.otc.2005.03.002

- 1 Eisen and Fischer. The F Wave. Recommendations for the Practice of Clinical
2 Neurophysiology: Guidelines of the International Federation of Clinical Physiology
3 (EEG Suppl. 52) Editors: G. Deuschl and A. Eisen, 1999
4
- 5 Elkowitz SJ, Dubin NH, Richards BE, Wilgis EF. Clinical utility of portable versus
6 traditional electrodiagnostic testing for diagnosing, evaluating, and treating carpal
7 tunnel syndrome. *Am J Orthop (Belle Mead NJ)*. 2005;34(8):362-364.
8
- 9 Emerson RG, Adams DC, Nagle KJ. Monitoring of spinal cord function intraoperatively
10 using motor and somatosensory evoked potentials. In: Chiappa K, editor. *Evoked
11 potentials in clinical medicine*. Third edition. ©1997. Lippincott-Raven Publishers.
12 Philadelphia –New York. Ch 20.
13
- 14 Emeryk-Szajewska B, Badurska B, Kostera-Pruszczyk A. Electrophysiological findings in
15 hereditary motor and sensory neuropathy type I and II--a conduction velocity
16 study. *Electromyogr Clin Neurophysiol*. 1998;38(2):95-101.
17
- 18 England JD, Franklin GM. Automated hand-held nerve conduction devices: raw data, raw
19 interpretations. *Muscle Nerve*. 2011;43(1):6-8. doi:10.1002/mus.21960
20
- 21 Erickson L, Costa V, McGregor M. Intraoperative neurophysiological monitoring during
22 spinal surgery. Montreal: Technology Assessment Unit of the McGill University
23 Health Centre (MUHC), 2005:39.
24
- 25 Fehlings MG, Brodke DS, Norvell DC, Dettori JR. The evidence for intraoperative
26 neurophysiological monitoring in spine surgery: does it make a difference?. *Spine
27 (Phila Pa 1976)*. 2010;35(9 Suppl):S37-S46. doi:10.1097/BRS.0b013e3181d8338e
28
- 29 Ferdjallah M, Wertsch JJ. Anatomical and technical considerations in surface
30 electromyography. *Phys Med Rehabil Clin N Am*. 1998;9(4):925-931.
31
- 32 Fisher MA. H reflexes and F waves. Fundamentals, normal and abnormal patterns. *Neurol
33 Clin*. 2002;20(2):339-vi. doi:10.1016/s0733-8619(01)00004-4
34
- 35 Fisher MA, Bajwa R, Somashekar KN. Routine electrodiagnosis and a multiparameter
36 technique in lumbosacral radiculopathies. *Acta Neurol Scand*. 2008;118(2):99-105.
37 doi:10.1111/j.1600-0404.2007.00987.x
38
- 39 Geisser ME, Ranavaya M, Haig AJ, et al. A meta-analytic review of surface
40 electromyography among persons with low back pain and normal, healthy controls. *J
41 Pain*. 2005;6(11):711-726. doi:10.1016/j.jpain.2005.06.008

- 1 Gooch CL, Pullman S. Electromyography, nerve conduction studies, and magnetic
2 stimulation. In: Rowland PL, editor. *Merritt's Neurology*. 11th edition. Lippincott
3 Williams and Wilkins. Ch 15.
- 4
- 5 Gooch CL, Weimer LH. The electrodiagnosis of neuropathy: basic principles and common
6 pitfalls. *Neurol Clin*. 2007;25(1):1-28. doi:10.1016/j.ncl.2007.01.011
- 7
- 8 Grassme R, Arnold D, Anders Ch, et al. Improved evaluation of back muscle SEMG
9 characteristics by modelling. *Pathophysiology*. 2005;12(4):307-312.
10 doi:10.1016/j.pathophys.2005.09.011
- 11
- 12 Gunnarsson T, Krassioukov AV, Sarjeant R, Fehlings MG. Real-time continuous
13 intraoperative electromyographic and somatosensory evoked potential recordings in
14 spinal surgery: correlation of clinical and electrophysiologic findings in a prospective,
15 consecutive series of 213 cases. *Spine (Phila Pa 1976)*. 2004;29(6):677-684.
16 doi:10.1097/01.brs.0000115144.30607.e9
- 17
- 18 Guse BH, Love MJ. Medical assessment and laboratory testing in psychiatry. In: Saydock
19 BJ, Saydock VA, editors. *Kaplan and Saydock's Comprehensive Textbook of
20 Psychiatry*. 8th ed, 2005. p. 919.
- 21
- 22 Haig AJ, Gelblum JB, Rechten JJ, Gitter AJ. Technology assessment: the use of surface
23 EMG in the diagnosis and treatment of nerve and muscle disorders. *Muscle Nerve*.
24 1996;19(3):392-395. doi:10.1002/(SICI)1097-4598(199603)19:3<392::AID-
25 MUS21>3.0.CO;2-T
- 26
- 27 Haig AJ, Tong HC, Yamakawa KS, et al. Spinal stenosis, back pain, or no symptoms at
28 all? A masked study comparing radiologic and electrodiagnostic diagnoses to the
29 clinical impression. *Arch Phys Med Rehabil*. 2006;87(7):897-903.
30 doi:10.1016/j.apmr.2006.03.016
- 31
- 32 Hammad M, Silva A, Glass J, Sladky JT, Benatar M. Clinical, electrophysiologic, and
33 pathologic evidence for sensory abnormalities in ALS. *Neurology*. 2007;69(24):2236-
34 2242. doi:10.1212/01.wnl.0000286948.99150.16
- 35
- 36 Heinonen P, Kautiainen H, Mikkelsen M. Erector spinae SEMG activity during forward
37 flexion and re-extension in ankylosing spondylitis patients. *Pathophysiology*.
38 2005;12(4):289-293. doi:10.1016/j.pathophys.2005.09.010
- 39
- 40 Hilburn JW. General principles and use of electrodiagnostic studies in carpal and cubital
41 tunnel syndromes. With special, attention to pitfalls and interpretation. *Hand Clin*.
42 1996;12(2):205-221.

- 1 Hogrel JY. Clinical applications of surface electromyography in neuromuscular
2 disorders. *Neurophysiol Clin.* 2005;35(2-3):59-71. doi:10.1016/j.neucli.2005.03.001
3
- 4 Höliner I, Haslinger V, Lütschg J, et al. Validity of the neurological examination in
5 diagnosing diabetic peripheral neuropathy. *Pediatr Neurol.* 2013;49(3):171-177.
6 doi:10.1016/j.pediatrneurol.2013.03.014
7
- 8 Holland NR. Intraoperative electromyography. *J Clin Neurophysiol.* 2002;19(5):444-453.
9 doi:10.1097/00004691-200210000-00007
10
- 11 Hu Y, Kwok JW, Tse JY, Luk KD. Time-varying surface electromyography topography as
12 a prognostic tool for chronic low back pain rehabilitation. *Spine J.* 2014;14(6):1049-
13 1056. doi:10.1016/j.spinee.2013.11.060
14
- 15 Jablecki CK, Andary MT, Floeter MK, et al. Practice parameter: Electrodiagnostic studies
16 in carpal tunnel syndrome. Report of the American Association of Electrodiagnostic
17 Medicine, American Academy of Neurology, and the American Academy of Physical
18 Medicine and Rehabilitation (Retired). *Neurology.* 2002;58(11):1589-1592.
19 doi:10.1212/wnl.58.11.1589
20
- 21 Jabre JF, Salzsieder BT, Gnemi KE. Criterion validity of the NC-stat automated nerve
22 conduction measurement instrument. *Physiol Meas.* 2007;28(1):95-104.
23 doi:10.1088/0967-3334/28/1/009
24
- 25 Jalovaara P, Niinimäki T, Vanharanta H. Pocket-size, portable surface EMG device in the
26 differentiation of low back pain patients. *Eur Spine J.* 1995;4(4):210-212.
27 doi:10.1007/BF00303412
28
- 29 Jameson LC, Janik DJ, Sloan TB. Electrophysiologic monitoring in
30 neurosurgery. *Anesthesiol Clin.* 2007;25(3):605-x. doi:10.1016/j.anclin.2007.05.004
31
- 32 Juel VC. Evaluation of neuromuscular junction disorders in the electromyography
33 laboratory. *Neurol Clin.* 2012;30(2):621-639. doi:10.1016/j.ncl.2011.12.012
34
- 35 Jurell KC. Surface EMG and fatigue. *Phys Med Rehabil Clin N Am.* 1998;9(4):933-ix.
36
- 37 Karami-Mohajeri S, Nikfar S, Abdollahi M. A systematic review on the nerve-muscle
38 electrophysiology in human organophosphorus pesticide exposure. *Hum Exp Toxicol.*
39 2014;33(1):92-102. doi:10.1177/0960327113489047

- 1 Katifi HA, Sedgwick EM. Evaluation of the dermatomal somatosensory evoked potential
2 in the diagnosis of lumbo-sacral root compression. *J Neurol Neurosurg Psychiatry*.
3 1987;50(9):1204-1210. doi:10.1136/jnnp.50.9.1204
4
- 5 Katirji B. The clinical electromyography examination. An overview. *Neurol Clin*.
6 2002;20(2):291-v. doi:10.1016/s0733-8619(01)00002-0
7
- 8 Katz JN, Simmons BP. Clinical practice. Carpal tunnel syndrome. *N Engl J Med*.
9 2002;346(23):1807-1812. doi:10.1056/NEJMcp013018
10
- 11 Katz RT. NC-stat as a screening tool for carpal tunnel syndrome in industrial workers. *J*
12 *Occup Environ Med*. 2006;48(4):414-418. doi:10.1097/01.jom.0000194151.30385.1a
13
- 14 Kaufman MA. Differential diagnosis and pitfalls in electrodiagnostic studies and special
15 tests for diagnosing compressive neuropathies. *Orthop Clin North Am*.
16 1996;27(2):245-252.
17
- 18 Kelleher MO, Tan G, Sarjeant R, Fehlings MG. Predictive value of intraoperative
19 neurophysiological monitoring during cervical spine surgery: a prospective analysis of
20 1055 consecutive patients. *J Neurosurg Spine*. 2008;8(3):215-221.
21 doi:10.3171/SPI/2008/8/3/215
22
- 23 Khan MH, Smith PN, Balzer JR, et al. Intraoperative somatosensory evoked potential
24 monitoring during cervical spine corpectomy surgery: experience with 508
25 cases. *Spine (Phila Pa 1976)*. 2006;31(4):E105-E113.
26 doi:10.1097/01.brs.0000200163.71909.1f
27
- 28 Kong X, Gozani SN, Hayes MT, Weinberg DH. NC-stat sensory nerve conduction studies
29 in the median and ulnar nerves of symptomatic patients. *Clin Neurophysiol*.
30 2006;117(2):405-413. doi:10.1016/j.clinph.2005.10.019
31
- 32 Kong X, Lesser EA, Megerian JT, Gozani SN. Repeatability of nerve conduction
33 measurements using automation. *J Clin Monit Comput*. 2006;20(6):405-410.
34 doi:10.1007/s10877-006-9046-8
35
- 36 Kostera-Pruszczyk A, Rowińska-Marcińska K, Owsiak S, Jeziński P, & Emeryk-
37 Szajewska B. Amplituda fali F w uszkodzeniach obwodowego układu nerwowego [F-
38 wave amplitude in peripheral nervous system lesions]. *Neurologia i neurochirurgia*
39 *polska*. 2004;38(6):465–470.

- 1 Kraft GH. Dermatomal somatosensory-evoked potentials in the evaluation of lumbosacral
2 spinal stenosis. *Phys Med Rehabil Clin N Am*. 2003;14(1):71-75. doi:10.1016/s1047-
3 9651(02)00080-3
4
- 5 Krassioukov AV, Sarjeant R, Arkia H, Fehlings MG. Multimodality intraoperative
6 monitoring during complex lumbosacral procedures: indications, techniques, and long-
7 term follow-up review of 61 consecutive cases. *J Neurosurg Spine*. 2004;1(3):243-253.
8 doi:10.3171/spi.2004.1.3.0243
9
- 10 Krivickas LS. Electrodiagnosis in neuromuscular disease. *Phys Med Rehabil Clin N Am*.
11 1998;9(1):83-vi.
12
- 13 Kwon BC, Jung KI, Baek GH. Comparison of sonography and electrodiagnostic testing in
14 the diagnosis of carpal tunnel syndrome. *J Hand Surg Am*. 2008;33(1):65-71.
15 doi:10.1016/j.jhsa.2007.10.014
16
- 17 Lall RR, Lall RR, Hauptman JS, et al. Intraoperative neurophysiological monitoring in
18 spine surgery: indications, efficacy, and role of the preoperative checklist. *Neurosurg*
19 *Focus*. 2012;33(5):E10. doi:10.3171/2012.9.FOCUS12235
20
- 21 Lange DJ, Trojaborg W. Electromyography and nerve conduction studies in neuromuscular
22 disease. In: *Merritt's Neurology*. Chapter 15. Copyright 2000 by Lippincott Williams
23 & Wilkins.
24
- 25 Larivière C, Arsenault AB, Gravel D, Gagnon D, Loisel P. Evaluation of measurement
26 strategies to increase the reliability of EMG indices to assess back muscle fatigue and
27 recovery. *J Electromyogr Kinesiol*. 2002;12(2):91-102. doi:10.1016/s1050-
28 6411(02)00011-1
29
- 30 Larivière C, Gagnon D, Loisel P. The comparison of trunk muscles EMG activation
31 between subjects with and without chronic low back pain during flexion-extension and
32 lateral bending tasks. *J Electromyogr Kinesiol*. 2000;10(2):79-91. doi:10.1016/s1050-
33 6411(99)00027-9
34
- 35 Leffler CT, Gozani SN, Cros D. Median neuropathy at the wrist: diagnostic utility of
36 clinical findings and an automated electrodiagnostic device. *J Occup Environ Med*.
37 2000;42(4):398-409. doi:10.1097/00043764-200004000-00015
38
- 39 Legatt AD. General Principles of Somatosensory Evoked Potentials: MedScape. Updated
40 Feb 2019. Retrieved on July 3, 2023 from
41 <http://emedicine.medscape.com/article/1139906-overview>

- 1 Lehman GJ, McGill SM. The importance of normalization in the interpretation of surface
2 electromyography: a proof of principle. *J Manipulative Physiol Ther.* 1999;22(7):444-
3 446. doi:10.1016/s0161-4754(99)70032-1
4
- 5 Lehman RM. A review of neurophysiological testing. *Neurosurg Focus.* 2004;16(4):ECP1.
6 Published 2004 Apr 15. doi:10.3171/foc.2004.16.4.14
7
- 8 Lesser EA, Starr J, Kong X, Megerian JT, Gozani SN. Point-of-service nerve conduction
9 studies: an example of industry-driven disruptive innovation in health care. *Perspect*
10 *Biol Med.* 2007;50(1):40-53. doi:10.1353/pbm.2007.0007
11
- 12 Linden RD, Zappulla R, Shileds CB. Intraoperative evoked potential monitoring. In:
13 Chiappa K, editor. *Evoked potentials in clinical medicine.* Third edition. ©1997.
14 Lippincott-Raven Publishers. Philadelphia – New York. Ch. 18
15
- 16 Liu X, Aziz TZ, Bain PG. Intraoperative monitoring of motor symptoms using surface
17 electromyography during stereotactic surgery for movement disorders. *J Clin*
18 *Neurophysiol.* 2005;22(3):183-191
19
- 20 Local Coverage Determination (LCD): NERVE CONDUCTION Studies and
21 Electromyography (L36526). Retrieved on July 3, 2023 from
22 [https://www.cms.gov/medicare-coverage-](https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=36526&ver=32&SearchType=Advanced&CoverageSelection=Both&NCSelection=NCA%7cCAL%7cNCD%7cMEDCAC%7cTA%7cMCD&ArticleType=Ed%7cKey%7cSAD%7cFAQ&PolicyType=Final&s=%26mdash%3b)
23 [database/view/lcd.aspx?lcdid=36526&ver=32&SearchType=Advanced&CoverageSel-](https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=36526&ver=32&SearchType=Advanced&CoverageSelection=Both&NCSelection=NCA%7cCAL%7cNCD%7cMEDCAC%7cTA%7cMCD&ArticleType=Ed%7cKey%7cSAD%7cFAQ&PolicyType=Final&s=%26mdash%3b)
24 [ection=Both&NCSelection=NCA%7cCAL%7cNCD%7cMEDCAC%7cTA%7cMCD](https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=36526&ver=32&SearchType=Advanced&CoverageSelection=Both&NCSelection=NCA%7cCAL%7cNCD%7cMEDCAC%7cTA%7cMCD&ArticleType=Ed%7cKey%7cSAD%7cFAQ&PolicyType=Final&s=%26mdash%3b)
25 [&ArticleType=Ed%7cKey%7cSAD%7cFAQ&PolicyType=Final&s=%26mdash%3b](https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=36526&ver=32&SearchType=Advanced&CoverageSelection=Both&NCSelection=NCA%7cCAL%7cNCD%7cMEDCAC%7cTA%7cMCD&ArticleType=Ed%7cKey%7cSAD%7cFAQ&PolicyType=Final&s=%26mdash%3b)
26
- 27 Lofland KR, Cassisi JE, Levin JB, Palumbo NL, Blonsky ER. The incremental validity of
28 lumbar surface EMG, behavioral observation, and a symptom checklist in the
29 assessment of patients with chronic low-back pain. *Appl Psychophysiol Biofeedback.*
30 2000;25(2):67-78. doi:10.1023/a:1009589524042
31
- 32 Maccabee PJ, Eberle LP, Stein IA, et al. Upper leg conduction time distinguishes
33 demyelinating neuropathies. *Muscle Nerve.* 2011;43(4):518-530.
34 doi:10.1002/mus.21909
35
- 36 Mahla ME, Black S, Cucchiara RF. Intraoperative monitoring of sensory evoked potentials.
37 In: Miller RD, editor. *Miller's Anesthesia*, 6th ed. Ch 38. Neurologic monitoring.
38 Copyright © 2005. Churchill Livingstone.
39
- 40 Malhotra NR, Shaffrey CI. Intraoperative electrophysiological monitoring in spine
41 surgery. *Spine (Phila Pa 1976).* 2010;35(25):2167-2179.
42 doi:10.1097/BRS.0b013e3181f6f0d0

- 1 Marciniak C, Armon C, Wilson J, Miller R. Practice parameter: utility of electrodiagnostic
 2 techniques in evaluating patients with suspected peroneal neuropathy: an evidence-
 3 based review. *Muscle Nerve*. 2005;31(4):520-527. doi:10.1002/mus.20308
 4
- 5 Meekins GD, So Y, Quan D. American Association of Neuromuscular & Electrodiagnostic
 6 Medicine evidenced-based review: use of surface electromyography in the diagnosis
 7 and study of neuromuscular disorders. *Muscle Nerve*. 2008;38(4):1219-1224.
 8 doi:10.1002/mus.21055
 9
- 10 Megerian JT, Kong X, Gozani SN. Utility of nerve conduction studies for carpal tunnel
 11 syndrome by family medicine, primary care, and internal medicine physicians. *J Am
 12 Board Fam Med*. 2007;20(1):60-64. doi:10.3122/jabfm.2007.01.060111
 13
- 14 Mendell JR, Sahenk Z. Clinical practice. Painful sensory neuropathy. *N Engl J Med*.
 15 2003;348(13):1243-1255. doi:10.1056/NEJMcp022282
 16
- 17 Meriggioli MN, Sanders DB. Advances in the diagnosis of neuromuscular junction
 18 disorders. *Am J Phys Med Rehabil*. 2005;84(8):627-638.
 19 doi:10.1097/01.phm.0000171169.79816.4c
 20
- 21 Mesrati F, Vecchierini MF. F-waves: neurophysiology and clinical value. *Neurophysiol
 22 Clin*. 2004;34(5):217-243. doi:10.1016/j.neucli.2004.09.005
 23
- 24 Mohseni Bandpei MA, Rahmani N, Majdoleslam B, Abdollahi I, Ali SS, Ahmad A.
 25 Reliability of surface electromyography in the assessment of paraspinal muscle fatigue:
 26 an updated systematic review. *J Manipulative Physiol Ther*. 2014;37(7):510-521.
 27 doi:10.1016/j.jmpt.2014.05.006
 28
- 29 Molloy FM, Shill HA, Kaelin-Lang A, Karp BI. Accuracy of muscle localization without
 30 EMG: implications for treatment of limb dystonia. *Neurology*. 2002;58(5):805-807.
 31 doi:10.1212/wnl.58.5.805
 32
- 33 Mondelli M, Aretini A, Arrigucci U, Ginanneschi F, Greco G, Sicurelli F. Clinical findings
 34 and electrodiagnostic testing in 108 consecutive cases of lumbosacral radiculopathy
 35 due to herniated disc. *Neurophysiol Clin*. 2013;43(4):205-215.
 36 doi:10.1016/j.neucli.2013.05.004
 37
- 38 Mullins GM, O'Sullivan SS, Neligan A, et al. Non-traumatic brachial plexopathies,
 39 clinical, radiological and neurophysiological findings from a tertiary centre. *Clin
 40 Neurol Neurosurg*. 2007;109(8):661-666. doi:10.1016/j.clineuro.2007.05.010

- 1 NeuMed®, Inc. Brevio® Nerve Conduction Monitoring System. Retrieved on July 1, 2023
2 from <http://www.neumedinc.com/products/brevio.htm>
3
- 4 NeuroMetrix®. Product Information NC-Stat®/ DPN Check®. Retrieved on July 1, 2023
5 from <http://www.dpncheck.com/>
6
- 7 Ney JP, van der Goes DN. Evidence-based guideline update: Intraoperative spinal
8 monitoring with somatosensory and transcranial electrical motor evoked potentials.
9 Report of the Therapeutics and Technology Assessment Subcommittee of the
10 American Academy of Neurology and the American Clinical Neurophysiology
11 Society. *Neurology*. 2012;79(3):292-294. doi:10.1212/WNL.0b013e3182637c24
12
- 13 Ng JK, Kippers V, Parnianpour M, Richardson CA. EMG activity normalization for trunk
14 muscles in subjects with and without back pain. *Med Sci Sports Exerc*.
15 2002;34(7):1082-1086. doi:10.1097/00005768-200207000-00005
16
- 17 Ng JK, Richardson CA, Parnianpour M, Kippers V. EMG activity of trunk muscles and
18 torque output during isometric axial rotation exertion: a comparison between back pain
19 patients and matched controls. *J Orthop Res*. 2002;20(1):112-121. doi:10.1016/S0736-
20 0266(01)00067-5
21
- 22 Ng JK, Richardson CA, Parnianpour M, Kippers V. Fatigue-related changes in torque
23 output and electromyographic parameters of trunk muscles during isometric axial
24 rotation exertion: an investigation in patients with back pain and in healthy
25 subjects. *Spine (Phila Pa 1976)*. 2002;27(6):637-646. doi:10.1097/00007632-
26 200203150-00013
27
- 28 North American Spine Society. Electromyogram and nerve conduction study. North
29 American Spine Society. Retrieved on July 3, 2023 from
30 <https://www.spine.org/KnowYourBack/Treatments/AssessmentTools/ElectrodiagnosticTesting>
31
32
- 33 Nuwer MR, Emerson RG, Galloway G, et al. Evidence-based guideline update:
34 intraoperative spinal monitoring with somatosensory and transcranial electrical motor
35 evoked potentials: report of the Therapeutics and Technology Assessment
36 Subcommittee of the American Academy of Neurology and the American Clinical
37 Neurophysiology Society. *Neurology*. 2012;78(8):585-589.
38 doi:10.1212/WNL.0b013e318247fa0e
39
- 40 Oddsson LI, Giphart JE, Buijs RJ, Roy SH, Taylor HP, De Luca CJ. Development of new
41 protocols and analysis procedures for the assessment of LBP by surface EMG
42 techniques. *J Rehabil Res Dev*. 1997;34(4):415-426

- 1 Oh SJ. Clinical Electromyography: Nerve Conduction Studies. 3d ed. Philadelphia, PA:
2 Lippincott Williams & Wilkins; 2003: 147-148
3
- 4 Omejec G, Žgur T, Podnar S. Diagnostic accuracy of ultrasonographic and nerve
5 conduction studies in ulnar neuropathy at the elbow. *Clin Neurophysiol.*
6 2015;126(9):1797-1804. doi:10.1016/j.clinph.2014.12.001
7
- 8 Palmieri RM, Ingersoll CD, Hoffman MA. The hoffmann reflex: methodologic
9 considerations and applications for use in sports medicine and athletic training
10 research. *J Athl Train.* 2004;39(3):268-277
11
- 12 Park KM, Shin KJ, Park J, Ha SY, Kim SE. The usefulness of terminal latency index of
13 median nerve and f-wave difference between median and ulnar nerves in assessing the
14 severity of carpal tunnel syndrome. *J Clin Neurophysiol.* 2014;31(2):162-168.
15 doi:10.1097/WNP.0000000000000041
16
- 17 Parker SL, Amin AG, Farber SH, et al. Ability of electromyographic monitoring to
18 determine the presence of malpositioned pedicle screws in the lumbosacral spine:
19 analysis of 2450 consecutively placed screws. *J Neurosurg Spine.* 2011;15(2):130-135.
20 doi:10.3171/2011.3.SPINE101
21
- 22 Pawar S, Kashikar A, Shende V, Waghmare S. The study of diagnostic efficacy of nerve
23 conduction study parameters in cervical radiculopathy. *J Clin Diagn Res.*
24 2013;7(12):2680-2682. doi:10.7860/JCDR/2013/7545.3731
25
- 26 Peach JP, McGill SM. Classification of low back pain with the use of spectral
27 electromyogram parameters. *Spine (Phila Pa 1976).* 1998;23(10):1117-1123.
28 doi:10.1097/00007632-199805150-00009
29
- 30 Pelosi L, Lamb J, Grevitt M, Mehdian SM, Webb JK, Blumhardt LD. Combined
31 monitoring of motor and somatosensory evoked potentials in orthopaedic spinal
32 surgery. *Clin Neurophysiol.* 2002;113(7):1082-1091. doi:10.1016/s1388-
33 2457(02)00027-5
34
- 35 Perkins BA, Grewal J, Ng E, Ngo M, Bril V. Validation of a novel point-of-care nerve
36 conduction device for the detection of diabetic sensorimotor polyneuropathy. *Diabetes*
37 *Care.* 2006;29(9):2023-2027. doi:10.2337/dc08-0500
38
- 39 Perkins BA, Orszag A, Grewal J, Ng E, Ngo M, Bril V. Multi-site testing with a point-of-
40 care nerve conduction device can be used in an algorithm to diagnose diabetic
41 sensorimotor polyneuropathy. *Diabetes Care.* 2008;31(3):522-524. doi:10.2337/dc07-
42 1227

- 1 Pullman SL, Goodin DS, Marquinez AI, Tabbal S, Rubin M. Clinical utility of surface
2 EMG: report of the therapeutics and technology assessment subcommittee of the
3 American Academy of Neurology (Retired). *Neurology*. 2000;55(2):171-177.
4 doi:10.1212/wnl.55.2.171
- 5
- 6 Rau, G., Disselhorst-Klug, C., & Silny, J. (1997). Noninvasive approach to motor unit
7 characterization: Muscle structure, membrane dynamics and neuronal control. *Journal*
8 *of Biomechanics*, 30(5), 441-446
- 9
- 10 Raynor BL, Lenke LG, Bridwell KH, Taylor BA, Padberg AM. Correlation between low
11 triggered electromyographic thresholds and lumbar pedicle screw malposition: analysis
12 of 4857 screws. *Spine (Phila Pa 1976)*. 2007;32(24):2673-2678.
13 doi:10.1097/BRS.0b013e31815a524f
- 14
- 15 Resnick DK, Choudhri TF, Dailey AT, et al. Guidelines for the performance of fusion
16 procedures for degenerative disease of the lumbar spine. Part 15: electrophysiological
17 monitoring and lumbar fusion. *J Neurosurg Spine*. 2005;2(6):725-732.
18 doi:10.3171/spi.2005.2.6.0725
- 19
- 20 Rotman MB, Enkvetchakul BV, Megerian JT, Gozani SN. Time course and predictors of
21 median nerve conduction after carpal tunnel release. *J Hand Surg Am*. 2004;29(3):367-
22 372. doi:10.1016/j.jhsa.2004.01.011
- 23
- 24 Ruddy: Kelley's Textbook of Rheumatology, 6th edition. Neurophysiology
25 (electrodiagnostic studies). ©2001 W.B. Saunders Company. Page 470.
- 26
- 27 Sanders DB, Howard JF. Disorders of neuromuscular transmission. In: Bradley: Neurology
28 in Clinical Practice, 5th edition. Ch 82. Copyright © 2008 Butterworth-Heinemann.
- 29
- 30 Schmidt K, Chinea NM, Sorenson EJ, Strommen JA, Boon AJ. Accuracy of diagnoses
31 delivered by an automated hand-held nerve conduction device in comparison to
32 standard electrophysiological testing in patients with unilateral leg symptoms. *Muscle*
33 *Nerve*. 2011;43(1):9-13. doi:10.1002/mus.21911
- 34
- 35 Schoeck AP, Mellion ML, Gilchrist JM, Christian FV. Safety of nerve conduction studies
36 in patients with implanted cardiac devices. *Muscle Nerve*. 2007;35(4):521-524.
37 doi:10.1002/mus.20690
- 38
- 39 Seubert CN, Mahla ME. Neurologic monitoring. Ch 46. In: Miller's Anesthesia. 7th ed.
40 Copyright © 2009 Churchill Livingstone

- 1 Sharan A, Groff MW, Dailey AT, et al. Guideline update for the performance of fusion
2 procedures for degenerative disease of the lumbar spine. Part 15: electrophysiological
3 monitoring and lumbar fusion. *J Neurosurg Spine*. 2014;21(1):102-105.
4 doi:10.3171/2014.4.SPINE14324
- 5
- 6 Snowden ML, Haselkorn JK, Kraft GH, et al. Dermatomal somatosensory evoked
7 potentials in the diagnosis of lumbosacral spinal stenosis: comparison with imaging
8 studies. *Muscle Nerve*. 1992;15(9):1036-1044. doi:10.1002/mus.880150908
- 9
- 10 Souza, T. (2009). *Differential Diagnosis and Management for the Chiropractor Protocols*
11 *1 and Algorithms*. 4th Ed. Boston: Jones and Bartlett Publishers
- 12
- 13 Stålberg E, Falck B. The role of electromyography in neurology. *Electroencephalogr Clin*
14 *Neurophysiol*. 1997;103(6):579-598. doi:10.1016/s0013-4694(97)00138-7
- 15
- 16 Stegeman DF, Blok JH, Hermens HJ, Roeleveld K. Surface EMG models: properties and
17 applications. *J Electromyogr Kinesiol*. 2000;10(5):313-326. doi:10.1016/s1050-
18 6411(00)00023-7
- 19
- 20 Storm SA, Kraft GH. The clinical use of dermatomal somatosensory evoked potentials in
21 lumbosacral spinal stenosis. *Phys Med Rehabil Clin N Am*. 2004;15(1):107-115.
22 doi:10.1016/s1047-9651(03)00107-4
- 23
- 24 Sutter MA, Eggspuehler A, Grob D, Porchet F, Jeszenszky D, Dvorak J. Multimodal
25 intraoperative monitoring (MIOM) during 409 lumbosacral surgical procedures in 409
26 patients. *Eur Spine J*. 2007;16 Suppl 2(Suppl 2):S221-S228. doi:10.1007/s00586-007-
27 0432-9
- 28
- 29 Tankisi H, Pugdahl K, Fuglsang-Frederiksen A, et al. Pathophysiology inferred from
30 electrodiagnostic nerve tests and classification of polyneuropathies. Suggested
31 guidelines. *Clin Neurophysiol*. 2005;116(7):1571-1580.
32 doi:10.1016/j.clinph.2005.04.003
- 33
- 34 Torvin Møller A, Winther Bach F, Feldt-Rasmussen U, et al. Functional and structural
35 nerve fiber findings in heterozygote patients with Fabry disease. *Pain*. 2009;145(1-
36 2):237-245. doi:10.1016/j.pain.2009.06.032
- 37
- 38 Triano JJ, Budgell B, Bagnulo A, et al. Review of methods used by chiropractors to
39 determine the site for applying manipulation. *Chiropr Man Therap*. 2013;21(1):36.
40 Published 2013 Oct 21. doi:10.1186/2045-709X-21-36

- 1 Trujillo-Hernández B, Huerta M, Trujillo X, Vásquez C, Pérez-Vargas D, Millán-Guerrero
2 RO. F-wave and H-reflex alterations in recently diagnosed diabetic patients. *J Clin*
3 *Neurosci.* 2005;12(7):763-766. doi:10.1016/j.jocn.2004.09.018
4
- 5 Tsai TM, Tsai CL, Lin TS, Lin CC, Jou IM. Value of dermatomal somatosensory evoked
6 potentials in detecting acute nerve root injury: an experimental study with special
7 emphasis on stimulus intensity. *Spine (Phila Pa 1976).* 2005;30(18):E540-E546.
8 doi:10.1097/01.brs.0000179311.87137.0d
9
- 10 Urban MK. Anesthesia for Orthopedic Surgery. In: Miller: Miller's Anesthesia, 7th edition.
11 Ch 70. Copyright © 2009 Churchill Livingstone.
12
- 13 U.S. Food and Drug Administration (FDA). CFR Title 21. Part 882. Neurological Devices.
14 Updated June 2023. Retrieved on July 3, 2023 from
15 [http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?CFRPart=](http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?CFRPart=882)
16 [882](http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?CFRPart=882)
17
- 18 U.S. Food and Drug Administration. Brevio. 510(k) Summary K012069. June 29, 2001.
19 Retrieved on July 3, 2023 from
20 http://www.accessdata.fda.gov/cdrh_docs/pdf/k012069.pdf
21
- 22 Vij N, Kiernan H, Miller-Gutierrez S, et al. Etiology Diagnosis and Management of Radial
23 Nerve Entrapment. *Anesth Pain Med.* 2021;11(1):e112823. Published 2021 Feb 14.
24 doi:10.5812/aapm.112823
25
- 26 Wang Y, Cui LY, Chen L, et al. Nerve conduction studies in patients with dermatomyositis
27 or polymyositis. *Chin Med J (Engl).* 2010;123(5):523-526.
28
- 29 Watson PJ, Booker CK, Main CJ, Chen AC. Surface electromyography in the identification
30 of chronic low back pain patients: the development of the flexion relaxation ratio. *Clin*
31 *Biomech (Bristol, Avon).* 1997;12(3):165-171. doi:10.1016/s0268-0033(97)00065-x
32
- 33 Yiannikas C. Short-latency somatosensory evoked potentials in peripheral nerve lesions,
34 plexopathies, and radiculopathies. In: Chiappa K, editor. *Evoked potentials in clinical*
35 *medicine.* Third edition. Lippincott-Raven Publishers ©1997. Philadelphia –New
36 York. Ch. 10
37
- 38 Zwarts MJ, Drost G, Stegeman DF. Recent progress in the diagnostic use of surface EMG
39 for neurological diseases. *J Electromyogr Kinesiol.* 2000;10(5):287-291.
40 doi:10.1016/s1050-6411(00)00020-1

- 1 Zwarts MJ, Stegeman DF. Multichannel surface EMG: basic aspects and clinical
- 2 utility. Muscle Nerve. 2003;28(1):1-17. doi:10.1002/mus.10358